Regulation of Pancreatic α and β Cell Function by the Bile Acid Receptor TGR5 by Prasanna Kumar, Divya
Virginia Commonwealth University 
VCU Scholars Compass 
Theses and Dissertations Graduate School 
2014 
Regulation of Pancreatic α and β Cell Function by the Bile Acid 
Receptor TGR5 
Divya Prasanna Kumar 
Follow this and additional works at: https://scholarscompass.vcu.edu/etd 
 Part of the Cellular and Molecular Physiology Commons, and the Endocrinology Commons 
 
© The Author 
Downloaded from 
https://scholarscompass.vcu.edu/etd/3591 
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It 
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars 
Compass. For more information, please contact libcompass@vcu.edu. 
Regulation	  of	  Pancreatic	  α	  and	  β	  Cell	  Function	  by	  the	  	  
Bile	  Acid	  Receptor	  TGR5	  	  
A dissertation submitted in partial fulfillment of the requirement for the degree of  
Doctor of Philosophy at Virginia Commonwealth University 
 
 
 
 
by 
 
 
 
 
Divya P. Kumar 
M.S. in Biotechnology 
 University of Mysore  
 Mysore, India  	  	  	  	  
Directors: Dr. Arun Sanyal and Dr. Murthy Karnam 
Departments of Internal Medicine and Physiology and Biophysics 
 
 
 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
November 2014 	  	  
	  	  
ii	  
ACKNOWLEDGEMENT 
 
 
 
I owe a debt of gratitude to my mentors Dr. Murthy Karnam and Dr. Arun Sanyal 
and find short of words to fully express my feelings for all the guidance and support they 
have provided throughout this journey. Dr. Karnam humbly leads by example and his 
amazing work ethics has always motivated me to remain focused and achieve this 
milestone. He is a wonderful mentor who is not only a good scientist but also a great 
human being. I equally thank Dr. Arun Sanyal for recognizing my potential. It’s been a 
great pleasure working with Dr. Sanyal and a rich learning experience. His perpetual 
energy and enthusiasm in research is always motivating. 
 I gratefully acknowledge the support of Dr. John Grider for his words of 
encouragement, support and being generous in sharing scientific ideas. My studies 
could not have been made possible without the insightful suggestions of my committee 
members, Dr. Phil Hylemon, Dr. Vijay Lyall, and Dr. Sunila Mahavadi. They were 
generous with their time and helpful with their comments and criticisms.  
 I must also thank Dr. Makhlouf who not only believed in me, but also inspired me 
and provided scientific advice along the way. I also extend my heartfelt thanks to Dr. 
Logothetis, Chair, Department of Physiology and Dr. De Felice for their support and 
making this graduate life a smooth and memorable journey.        
 
	  	  
iii	  
 Most importantly I would like to thank all the members of the GI and taste group.  
I feel fortunate to have such a wonderful and happy work place. Special thanks to other 
faculty members of the GI and taste group- Dr. Kuemmerle, Dr. Qiao, Dr. Biber and Dr. 
De Simonne. I would like to thank all the present and former members in the laboratory 
who have made this journey wonderful by being good friends. Thank you Senthil, 
Ruizhe, Derek, Chao, Ancy, Reem, Sayak, Mohammad, Norm, Vanitha, Chunmei, Zack, 
Miao, Shane, Ji Qian. Special thanks to Shobha Mummalaneni for her kind care and 
help with Ca2+ measurements. Thanks to Christina for her willingness to help at all 
times. My sincere thanks to Dr. Craig Nunemaker (University of Virginia) and Kathryn 
for their excellent support with the training of islet isolation procedure.  
 I also extend thanks to Farid for his support and patience. Thanks to Drs. Min, 
Sophie, Amon and all other members in Dr. Sanyal’s lab. Special thanks to my friend, 
Yogitha for her sincere effort and patience in proof reading the dissertation. I also 
sincerely thank my friends Dr. Sudha Koka and Dr. Krishnamurthy Boini for always 
being there for me.   
As always, my parents and sisters have provided enthusiastic support, and 
unqualified love.  My deepest gratitude to them for everything they provided and special 
love to my dearest nephew for providing us enormous happiness. Thanks also to my 
parents-in-law and brother-in-law. Last but not the least, I am grateful to my dear 
husband, Dr. Prasanna Kumar for his unwavering support when it matters the most. 
	  	  
iv	  
 
 
 
 
 
TABLE OF CONTENTS 
 
 
 
 Page 
 
Acknowledgement………………………………………………………………………. 
 
ii 
Table of Content……………………………………………………………………….... 
 
iv 
List of Tables…………………………………………………………………………….. 
 
ix 
List of Figures……………………………………………………………………………. 
 
x 
List of Abbreviations…………………………………………………………………….. 
 
xvi 
Abstract…………………………………………………………………………………… 
 
xviii 
CHAPTER 1. GENERAL INTRODUCTION………………………………………….. 
 
1–20 
          1.1. Bile Acids……………………………………………………………………. 1 
          1.2. Bile acid synthesis and regulation………………………………………… 
 
2 
          1.3. Bile acid transport…………………………………………………………... 3 
          1.4. Bile acid receptors………………………………………………………….. 
 
6 
                    1.4.1. FXR…………………………………………………………………. 
 
6 
                    1.4.2. TGR5……………………………………………………………….. 
 
8 
          1.5. Physiological significance of bile acids…………………………………… 
 
9 
                    1.5.1. Functions via FXR…………………………………………………. 
 
9 
                    1.5.2. Functions via TGR5……………………………………………..... 
 
10 
          1.6. Pancreas……………………………………………………………………... 
 
13 
	  	  
v	  
                    1.6.1. Exocrine Pancreas………………………………………………… 
 
13 
                    1.6.2. Endocrine Pancreas…………………………………………….... 
 
15 
          1.7. GPCRs and Pancreatic islets……………………………………………… 
 
16 
                    1.7.1. GLP-1 receptor……………………………………………………. 
 
17 
                    1.7.2. Physiological effects of GLP-1…………………………………... 
 
17 
          1.8. Bile acids and GLP-1………………………………………………………. 
 
19 
CHAPTER 2. REGULATION OF INSULIN SECRETION IN PANCREATIC β 
                      CELLS BY THE BILE ACID RECEPTOR TGR5……………………. 
 
 
21–57 
          2.1. Introduction………………………………………………………………….. 
 
21 
          2.2. Materials and Methods 
 
 
                    2.2.1. Materials…………………………………………………………… 
 
23 
                    2.2.2. Cell culture………………………………………………………… 
 
24 
                    2.2.3. Isolation and maintenance of mouse islets……………………. 
 
24 
                    2.2.4. RNA isolation and RT-PCR analysis…………………………… 
 
25 
                    2.2.5. Western blot analysis……………………………………………. 
 
27 
                    2.2.6. Assay for identification of activated G proteins……………….. 
 
27 
                    2.2.7. Assay for adenylyl cyclase activity……………………………... 
 
28 
                    2.2.8. Assay for phosphoinoside (PI) hydrolysis……………………… 
 
28 
                    2.2.9. Measurement of intracellular calcium………………………….. 
 
29 
                    2.2.10. Measurement of insulin secretion…………………………….. 
 
29 
                    2.2.11. Statistical analysis………………………………………………. 
 
30 
          2.3. Results 
 
 
                    2.3.1. Expression of TGR5 in human and murine pancreatic islets 
                    and in pancreatic β cells………………………………………………… 
30 
	  	  
vi	  
	  
                    2.3.2. Stimulation of insulin secretion by TGR5 ligands…………….. 31 	  
                    2.3.3. Signaling mechanisms involved in TGR5-mediated insulin 
                    secretion in pancreatic β cells………………………………………….. 
32 	  
                          2.3.3.1. Activation of Gαs by TGR5 selective ligands…………… 
  
32 
                          2.3.3.2. Activation of adenylyl cyclase by TGR5 selective ligands	  	   33 
                          2.3.3.3. Activation of Epac (cAMP-dependent exchange factor) 
                          by TGR5 selective ligands…………………………………………. 
 
33 
                          2.3.3.4. Activation of PI hydrolysis by TGR5 selective ligands….	   34 
                          2.3.3.5. Release of Calcium by selective TGR5 ligands……….. 35 
                          2.3.3.6. Signaling pathways involved in TGR5-mediated insulin 
                          secretion in pancreatic β cells………………………………………	  
 
35 
          2.4. Discussion………………………………………………………................. 
 
36 
CHAPTER 3. REGULATION OF GLUCAGON SECRETION IN PANCREATIC α 
                      CELLS BY THE BILE ACID RECEPTOR TGR5……………………. 
 
58–71 
          3.1. Introduction…………………………………………………………………. 
 
58 
          3.2. Materials and Methods 
 
 
                    3.2.1. Materials…………………………………………………………... 
 
60 
                    3.2.2. Cell culture………………………………………………………... 
 
61 
                    3.2.3. Isolation and maintenance of mouse islets……………………. 
 
61 
                    3.2.4. RNA isolation and RT-PCR analysis…………………………… 
 
62 
                    3.2.5. Western blot analysis……………………………………………. 
 
62 
                    3.2.6. Measurement of glucagon secretion…………………………… 
 
62 
                    3.2.7. Statistical analysis……………………………………………….. 
 
63 	  
	  	  
vii	  
	  
          3.3. Results 
 
 
                    3.3.1. Expression of TGR5 in pancreatic α, β and δ cell lines and 
                    mouse islets …………………………………………………………….. 
 
63 
                    3.3.2. Stimulation of glucagon secretion by TGR5 ligands in αTC1-6 
                    cells……………………………………………………………………….. 
63 	  
                    3.3.3. Stimulation of glucagon secretion by TGR5 ligands in mouse 
                    islets …………………………………………….................................... 
 
64 
          3.4. Discussion………………………………………………………................ 
 
64 
CHAPTER 4. REGULATION OF HYPERGLYCEMIA-INDUCED PC1 
                      EXPRESSION AND GLP-1 SECRETION IN PANCREATIC α 
                      CELLS BY TGR5………………………………………………………. 
 
71-122 
          4.1. Introduction…………………………………………………………………. 
 
72 
          4.2. Materials and Methods 
 
 
                    4.2.1. Materials…………………………………………………………... 
 
74 
                    4.2.2. Cell culture……………………………………………………….. 
 
75 
                    4.2.3. Isolation and maintenance of mouse islets…………………… 
 
76 
                    4.2.4. RNA isolation and RT-PCR analysis…………………………… 
 
76 
                    4.2.5. Western blot analysis……………………………………………. 
 
76 
                    4.2.6. Assay for phosphoinoside (PI) hydrolysis …………………….. 
 
77 
                    4.2.7. Transfection of PC1 plasmid into αTC1- 6 cells………………. 
 
77 
                    4.2.8. PC1 promoter activity assay……………………………………. 
 
77 
                    4.2.9. Measurement of GLP-1 secretion……………………………… 
 
78 
                    4.2.10. Measurement of GLP-1 secretion……………………………. 
 
78 
                    4.2.11. Statistical Analysis……………………………………………... 
 
79 
	  	  
viii	  
	  
          4.3. Results 
 
 
                    4.3.1. Expression of TGR5 under hyperglycemia…………………… 82 
                    4.3.2. Differential expression of PC1 and PC2 in pancreatic α, β and 
                    δ cell lines and mouse islets…………………………………………………………. 	   82 
                    4.3.3. Hyperglycemia-induced PC1 expression is augmented by  
                    INT-777…………………………………………………………………… 
 
83 
                    4.3.4. Signaling mechanisms involved in TGR5-mediated PC1 
                    expression in pancreatic α cells………………………………………..	   84 	  
                    4.3.5. Hyperglycemia-induced GLP-1 secretion is augmented by 
                    TGR5 ligands…………………………………………………………….	  
 
86 
                    4.3.6. Signaling mechanisms involved in TGR5-mediated GLP-1 
                    secretion in pancreatic α cells………………………………………….	  
 
87 
                    4.3.7. Regulation of pancreatic β cell function by GLP-1 released  
                    from α cells in response to bile acids…………………………………. 
 
89 
          4.4. Discussion………………………………………………………................ 
 
91 
CHAPTER 5. GENERAL DISCUSSION…………………………………………….. 
 
123 
REFERENCES………………………………………………………………………… 
 
130 
VITA……………………………………………………………………………………… 
 
143 	  
	  	  
ix	  
LIST OF TABLES 
 
 
 
 
  Page 
 
Table 1. GPCRs and their effect on insulin secretion in pancreatic β cells……. 
 
20 
Table 2. RT-PCR primer sequences……………………………………………….. 80 
Table 3. Primary and Secondary antibodies………………………………………. 
 
81 
 
 
 
 
 
	  	  
x	  
LIST OF FIGURES 
 
 
 
  Page 
 
Figure 1. 
 
Enterohepatic circulation of bile acids………………………………........ 4 
Figure 2. 
 
Schematic representation of the activation of TGR5 and FXR by bile 
acids…………………………………………………………………………. 
 
7 
Figure 3. 
 
A diagrammatic representation of the functional significance of 
TGR5……………………………………………………………………….... 
 
14 
Figure 4. 
 
Isolation and culture of mouse islets…………………………………....... 40 
Figure 5. 
 
Expression of TGR5 in pancreatic β cell lines…………………………… 41 
Figure 6. 
 
Expression of TGR5 in human and mouse pancreatic islets…………... 42 
Figure 7. 
 
Stimulation of insulin secretion by oleanolic acid (OA) in MIN6 cells…. 43 
Figure 8. 
 
Stimulation of insulin secretion by lithocholic acid (LCA) in MIN6 cells. 44 
Figure 9. 
 
Stimulation of insulin secretion by TGR5 ligands in mouse pancreatic 
islets………………………………………………………………………….. 
 
45 
Figure 10. 
 
Stimulation of insulin secretion by TGR5 ligands in human pancreatic 
islets………………………………………………………………………….. 
 
46 
Figure 11. 
 
Selective activation of Gαs by OA in MIN6 cells………………………… 47 
Figure 12. 
 
Selective activation of Gαs by INT-777 in MIN6 cells…………………… 48 
Figure 13. 
 
Activation of adenylyl cyclase by TGR5 ligands in MIN6 cells………… 49 
Figure 14. 
 
Effect of PKA inhibitor on OA-induced insulin secretion………………... 50 
	  	  
xi	  
 
Figure 15. 
 
Schematic representation of cAMP-mediated signaling pathway……... 51 
Figure 16. 
 
Stimulation of insulin secretion by the selective Epac ligand………….. 52 
Figure 17. 
 
Expression of Epac1, Epac2 or PLC-ε in MIN6 cells, mouse and 
human islets…………………………………………………………………. 
 
53 
Figure 18. 
 
Activation of PI hydrolysis by TGR5 or Epac ligand in MIN6 cells…….. 54 
Figure 19. Release of intracellular calcium by TGR5 ligands………………………. 
 
55 
Figure 20. 
 
Effect of Gαs and PI hydrolysis inhibitor and calcium chelator on OA-
induced insulin secretion…………………………………………………… 
 
56 
Figure 21. 
 
Schematic representation of the signaling pathway coupled to TGR5 
receptors to mediate insulin secretion from pancreatic β cells………… 
 
57 
Figure 22. 
 
Expression of TGR5 in pancreatic α, β and δ cell lines and mouse 
islets………………………………………………………………………….. 
 
68 
Figure 23. 
 
Stimulation of glucagon secretion by TGR5 ligands in αTC1-6 cells…. 69 
Figure 24. 
 
Stimulation of glucagon secretion by INT-777 or LCA in αTC1-6 cells.. 70 
Figure 25. 
 
Stimulation of glucagon secretion by TGR5 ligands in mouse 
pancreatic islets…………………………………………………………….. 
 
71 
Figure 26. 
 
Cell lines used in the study………………………………………………… 95 
Figure 27. 
 
Effect of glucose on TGR5 expression in mouse islets………………… 96 
Figure 28. 
 
Effect of glucose on TGR5 expression in αTC1-6 and MIN6 cells……. 97 
Figure 29. 
 
Regulation of insulin secretion from pancreatic β cells via GLP-1 
(Endocrine and paracrine mechanisms)…………………………………. 
98 
Figure 30. 
 
Processing of proglucagon………………………………………………… 99 
Figure 31. 
 
Differential expression of PC1 and PC2 in pancreatic α, β and δ cell 
lines and mouse islets……………………………………………………… 
 
100 
Figure 32. 
 
Effect of glucose and INT-777 on PC2 expression in αTC1-6 cells…… 101 
 
	  	  
xii	  
Figure 33. 
 
Increased PC1 expression in response to glucose and INT-777 in 
αTC1-6 cells…………………………………………………………………. 
 
102 
Figure 34. 
 
Increase in PC1 expression in response to glucose and INT-777 in 
control mouse islets………………………………………………………… 
 
103 
Figure 35. 
 
Increase in PC1 expression in response to INT-777 in diabetic mouse 
islets………………………………………………………………………….. 
 
104 
Figure 36. 
 
Increased PC1 expression in response to glucose and INT-777 in 
human islets…………………………………………………………………. 
 
105 
Figure 37. 
 
Increase in PC1 promoter activity in response to glucose and INT-777 
in αTC1-6 cells………………………………………………………………. 
 
106 
Figure 38. 
 
Effect of Gαs and PKA inhibitors on INT-777-induced PC1 promoter 
activity………………………………………………………………………... 
 
107 
Figure 39. 
 
Activation of CREB in response to glucose and INT-777 in αTC1-6 
cells…………………………………………………………………………... 
 
108 
Figure 40. 
 
Activation of CREB in response to INT-777 in db/db mouse islets……. 109 
Figure 41. 
 
Schematic representation of the signaling pathway coupled to TGR5 
receptors to mediate PC1 expression in pancreatic α cells……………. 
 
110 
Figure 42. 
 
Augmentation of hyperglycemia-induced GLP-1 secretion by TGR5 
ligands in αTC1-6 cells……………………………………………………... 
 
111 
Figure 43. 
 
Augmentation of hyperglycemia-induced GLP-1 secretion by TGR5 
ligands in control mouse islets…………………………………………….. 
 
112 
Figure 44. 
 
Augmentation of GLP-1 secretion by INT-777 in diabetic (db/db) 
mouse islets…………………………………………………………………. 
 
113 
Figure 45. 
 
Stimulation of hyperglycemia-induced GLP-1 secretion by TGR5 
ligands in human islets…………………………………………………….. 
 
114 
Figure 46. 
 
Effect of PKA inhibitor on INT-777-induced GLP-1 secretion………….. 115 
Figure 47. 
 
Stimulation of GLP-1 secretion by Epac ligand………………………….. 116 
Figure 48. Expression of Epac1, Epac2 or PLC-ε in αTC1-6 cells………………… 117 
	  	  
xiii	  
 
Figure 49. 
 
Activation of PI hydrolysis by TGR5 or Epac ligand in αTC1-6 cells…. 118 
Figure 50. 
 
Effect of Gαs, PI hydrolysis, Epac2 inhibitor and calcium chelator on 
INT-777-induced GLP-1 release………………………………………….. 
 
119 
Figure 51. 
 
Schematic representation of the signaling pathway coupled to TGR5 
receptors to mediate PC1 expression and GLP-1 secretion from 
pancreatic α cells…………………………………………………………… 
 
120 
Figure 52. 
 
Effect of Exendin (9-39) on INT-777-induced insulin secretion in 
human islets…………………………………………………………………. 
 
121 
Figure 53. 
 
Regulation of pancreatic α and β cell function by the bile acid receptor 
TGR5…………………………………………………………………………. 
 
122 
	  	  
	  	  
xiv	  
LIST OF ABBREVIATIONS	  
 
 
 
AC…………………………..... 
 
Adenylyl cyclase 
AEBSF………………………. 
 
4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride 
 
ASBT…………………........... 
 
Apical sodium dependent bile acid transporter 
ATP…………………………… 
 
Adenosine triphosphate 
BA…………………………..... 
 
Bile acids 
BAPTA………………………. 1,2-bis(o-aminophenoxy)ethane-N,N,N1,N1-tetracetic acid 
 
bp…………………………….. 
 
Base pair 
 
BSA………………………….. 
 
Bovine serum albumin 
CA…………………………..... 
 
Cholic acid 
cAMP……………………….... 
 
Cyclic adenosine monophosphate 
CAR………………………….. 
 
Constitutive androstane receptor 
CDCA………………………... 
 
Chenodeoxycholic acid 
CYP7A1……………………... 
 
Cytochrome P450 7A1 
DCA………………………….. 
 
Deoxycholic acid 
DMEM………………………... 
 
Dulbecco’s modified eagle medium 
DNA…………………………... 
 
Deoxyribonucleic acid 
DPP-IV……………………….. 
 
Dipeptidyl peptidase- 4 
ELISA………………………… 
 
Enzyme linked immunosorbent assay 
 
	  	  
xv	  	  
Epac………………………….. 
 
cAMP-dependent exchange factor 
FBS…………………………. 
 
Fetal bovine serum 
FGF19……………………… 
 
Fibroblast growth factor 19 
FPR…………………………. 
 
Formyl-peptide receptors 
FXR…………………………. 
 
Farnesoid X receptor 
GAPDH……………………... 
 
Glyceraldehyde 3 phosphate dehydrogenase 
GLP-1………………………. 
 
Glucagon like peptide-1 
GLUT………………………… 
 
Glucose transporter 2 
GPCR……………………….. 
 
G protein coupled receptors 
GSIS………………………... 
 
Glucose stimulated insulin secretion 
HBSS………………………... 
 
Hank’s balanced salt solution 
HNF-4α……………………… 
 
Hepatocyte nuclear factor 4 alpha 
IBABP……………………….. 
 
Ileal bile acid binding protein 
IBMX………………………… 
 
3-isobutyl-1-methylxanthine 
IP3…………………………… 
 
Inositol triphosphate 
LCA………………………..... 
 
Lithocholic acid 
LRH-1……………………….. 
 
Liver receptor homolog-1 
MRP………………………… 
 
Multidrug resistance-associated protein 
NTCP………………………... 
 
Na+-taurocholate cotransporting polypeptide 
OA…………………………… Oleanolic acid 
 
OATP……………………….. 
 
Organic anion transporting polypeptide 
OST………………………….. Organic solute transporter 
	  	  
xvi	  
 
PC…………………………… 
 
Prohormone convertase 
PCR……………………….... 
 
Polymerase chain reaction 
PI……………………………. 
 
Phosphatidylinositol 
PKA………………………… 
 
Protein kinase A 
PKI………………………….. 
 
Protein kinase A inhibitor 
PLC-ε……………………….. 
 
Phospholipase C- epsilon 
PXR………………………… 
 
Pregnane X receptor 
RNA………………………… 
 
Ribonucleic acid 
RPMI……………………….. 
 
Roswell park memorial institute media 
S-EMCA…………………….  
 
6α-Ethyl-23(S)-methylcholic Acid 
S1PR……………………….. 
 
Sphingosine-1 phosphate receptor 
SDS-PAGE………………… 
 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
 
SHP………………………… 
 
Short heterodimer partner 
StarD1……………………... 
 
Steroidogenic acute regulatory domain containing protein 1 
STZ…………………………. 
 
Streptozotocin 
T2D…………………………. 
 
Type 2 Diabetes Mellitus 
TBST……………………….. 
 
Tris buffered saline with tween-20 
TGR5……………………….. 
 
Takeda G-protein coupled receptor clone 5 
VDR………………………… 
 
Vitamin D receptor 
WT………………………….. 
 
Wild type 	  
	  	  
xvii	  
SYMBOLS 
 
α……………………………... 
 
Alpha 
β……………………………... 
 
Beta 
δ……………………………... 
 
Delta 
 
UNITS 
 
%......................................... 
 
Percent 
0C…………………………… 
 
Degree celsius 
Da…………………………… 
 
Dalton 
g…………………………….. 
 
Gram 
h…………………………….. 
 
Hour(s) 
l……………………………… 
 
Liter 
M……………………………. 
 
Molar (moles/l) 
min………………………….. 
 
Minutes 
sec………………………….. 
 
Second(s) 
vol…………………………… 
 
Volume 	  
METRIC PREFIXES 
 
m……………………………. 
 
Milli 
µ…………………………….. 
 
Micro 
n…………………………….. 
 
Nano 
p…………………………….. 
 
Pico 	  
ABSTRACT	  
 
 
 
REGULATION	  OF	  PANCREATIC	  α	  AND	  β	  CELL	  FUNCTION	  BY	  THE	  BILE	  ACID	  RECEPTOR	  
TGR5	  
	  
Divya P. Kumar 
	  
A dissertation submitted in partial fulfillment of the requirement for the degree of  
Doctor of Philosophy at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2014 
 
Directors: Dr. Arun Sanyal and Dr. S. Murthy Karnam 
Departments of Internal Medicine and Physiology and Biophysics 
 
 
 
 The discovery that bile acids act as endogenous ligands of the membrane 
receptor TGR5 and the nuclear receptor FXR increased their significance as regulators 
of cholesterol, glucose and energy metabolism. Activation of TGR5, expressed on 
enteroendocrine L cells, by bile acids caused secretion of GLP-1, which stimulates 
insulin secretion from pancreatic β cells. Expression of TGR5 on pancreatic islet cells 
and the direct effect of bile acids on the endocrine functions of pancreas, however, are 
not fully understood. The aim of this study was to identify the expression of TGR5 in 
pancreatic islet cells and determine the effect of bile acids on insulin secretion. 
Expression of TGR5 was identified by quantitative PCR and western blot in islets from 
human and mouse, and in α (αTC1-6) and β (MIN6) cells. Release of insulin, glucagon 
and GLP-1 were measured by ELISA. The signaling pathways coupled to TGR5
	  
 activation were identified by direct measurements such as stimulation of G proteins, 
adenylyl cyclase activity, PI hydrolysis and intracellular Ca2+ in response to bile acids; 
and confirmed by the use of selective inhibitors that block specific steps in the signaling 
pathway. Our studies identified the expression of TGR5 receptors in β cells and 
demonstrated that activation of these receptors by both pharmacological ligands 
(oleanolic acid (OA) and INT-777) and physiological ligands (lithocholic acid, LCA) 
induced insulin secretion. TGR5 receptors are also expressed in α cells and, activation 
of TGR5 by OA, INT-777 and LCA at 5 mM glucose induced release of glucagon, which 
is processed from proglucagon by the selective expression of prohormone convertase 2 
(PC2). However, under hyperglycemia, activation of TGR5 in α cells augmented the 
glucose-induced increase in GLP-1 secretion, which in turn, stimulated insulin secretion. 
Secretion of GLP-1 from α cells reflected TGR5-mediated increase in PC1 promoter 
activity and PC1 expression, which selectively converts proglucagon to GLP-1. The 
signaling pathway activated by TGR5 to mediate insulin and GLP-1 secretion involved 
Gs/cAMP/Epac/PLC-ε/Ca2+. These results provide insight into the mechanisms involved 
in the regulation of pancreatic α and β cell function by bile acids and may lead to new 
therapeutic avenues for the treatment of diabetes.  
	  	   1	  
CHAPTER	  1 
GENERAL	  INTRODUCTION	  
	  
1.1. Bile acids 
 Bile acids, the active constituent of bile, are synthesized from cholesterol in the 
hepatocytes and secreted into the bile canaliculi to be stored in the gallbladder [1].  In 
response to a meal, the gallbladder contracts and the bile flows into the small intestine. 
Being amphipathic molecules, bile acids aid in the emulsification of lipids and facilitate 
the absorption of lipid nutrients and lipid soluble vitamins [2]. Nearly 95% of the bile 
acids that are secreted into the small intestine are transported back to the liver from the 
distal part of the ileum and colon via a process known as enterohepatic circulation 
(Figure 1). The bile acid transport is achieved by both passive diffusion as well as 
active transport  [3]. Consequently, a significant amount of bile acids spill over into the 
systemic circulation, which is generally less than 5 µM under fasting conditions and 
increases up to 15 µM postprandially [4]. Remaining 5% of the bile acids that escape 
absorption from the intestine is lost in the feces, a major route for the elimination of 
excess cholesterol from the body [1,5]. In addition to their established roles in 
cholesterol homeostasis and lipid digestion, bile acids also act as signaling molecules. 
With the identification of the bile acid receptors, both the endocrine and paracrine 
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functions of bile acids have become evident [6]. There has been an increasing 
development in understanding bile acid signaling, and bile acid receptors have become 
an attractive therapeutic target for the treatment of diseases such as metabolic 
syndrome and diabetes. 
1.1. Bile acid synthesis and regulation 
 Bile acid synthesis is a complex multistep process. There are 2 major bile acid 
biosynthetic pathways– the classical or neutral pathway and the acidic pathway. Bile 
acid synthesis from the classical pathway (75%) is initiated by CYP7A1 (Cholesterol 7 
alpha-hydroxylase or Cytochrome P450 7A1), which is expressed only in the 
hepatocytes, whereas, the acidic pathway (25%) initiated by mitochondrial CYP27A1 is 
expressed in macrophages and many other tissues [7]. It is noteworthy that all the 
essential enzymes for the conversion of cholesterol into bile acids reside only in the 
liver, which is the main site of synthesis [8]. The rate limiting steps in the classical 
pathway and the acidic pathway are 7α-hydroxylation of cholesterol by CYP7A1 and the 
transport of free cholesterol to the inner mitochondrial membrane by StarD1, 
respectively [7,9]. In humans, the primary bile acids produced in the liver are cholic acid 
(CA) and chenodeoxycholic acid (CDCA), whereas cholic acid and muricholic acid form 
the primary bile acid pool in mice. Primary bile acids are either glycine or taurine 
conjugated. Upon reaching the large intestine, they undergo deconjugation and 
dehydroxylation by the bacteria present in the gut forming secondary bile acids, which 
consist of lithocholic acid (LCA) and deoxycholic acid (DCA) in humans [10,11]. The 
secondary bile acids (unconjugated) are passively absorbed by the epithelial cells of the 
distal ileum, whereas the conjugated bile acids are actively transported via bile acid 
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transporters [12]. Bile acids consist of a steroid core and a side chain with carboxyl 
group. The number and position of hydroxyl groups on the steroid core determine the 
hydrophilic or hydrophobic nature of the bile acids. The primary bile acids are more 
hydrophilic than the secondary bile acids, and taurine conjugates are more hydrophilic 
than the glycine ones [13].  
    Bile acid synthesis is highly regulated. The basal rate of synthesis of bile acids in 
the liver is ~0.6 g per day in healthy humans, the amount sufficient to replace the lost 
bile acids in the feces. The total bile acid pool in the gastrointestinal tract is ~ 3 g and 
this pool recirculates ~ 4 to 12 times per day. If the reabsorption of bile acids is 
defective, de novo synthesis of bile acids in the liver increases up to 4 to 6 g per day. As 
high concentrations of bile acids are cytotoxic, bile acids regulate their own metabolism 
by exerting a negative feedback on their synthesis [5,7,14,15]. The bile acid feedback 
repression mechanism is governed by the interplay of several nuclear receptors to 
inhibit the transcription of CYP7A1 gene, the rate-limiting enzyme in bile acid synthesis 
[16]. In addition, factors like diet, nutrients, cytokines and hormones also regulate the 
expression of CYP7A1, the rate-limiting enzyme [17].  
1.3. Bile Acid Transport  
          Bile acid homeostasis is maintained by a balance between bile acid synthesis, 
secretion and reabsorption [7,9,17].  Bile acids are absorbed by both passive and active 
mechanisms. Passive absorption of bile acids occurs along the entire small intestine 
and colon. At the normal pH of the intestine (5.5 to 6.5), majority of the unconjugated 
bile acids exist in protonated or neutral form, and a very small amount of glycine-
conjugated or taurine-conjugated bile acids are protonated [11]. Thus, the unconjugated  
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Figure 1. Enterohepatic circulation of bile acids. Bile acids synthesized from 
cholesterol in the liver are secreted into the bile canaliculi and stored in the gallbladder. 
In response to a meal, the gallbladder contracts and the bile flows into the intestine 
facilitating the absorption of lipid nutrients and lipid soluble vitamins. Nearly 95% of the 
bile acids are transported back to the liver from the distal part of the ileum and colon via 
a process known as enterohepatic circulation and the remaining 5% of the bile acid pool 
is lost in the feces. Pharmacol Rev. 2014, 66: 948-983 [9]. 
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bile acids are absorbed by passive diffusion, however it is less intense than the active 
absorption [3,12]. Majority of bile acids in the ileum are conjugated and exist in anionic 
form. Hence the entry and exit of conjugated bile acids in the intestine and hepatocytes 
require active transport system, as they cannot cross the plasma membrane [5,7]. Bile 
acid transporters play an important role in modulating bile acid signaling by controlling 
the flux of bile acids [9,18].   
     The conjugated bile acids are actively absorbed in the terminal ileum via apical 
sodium-dependent bile acid transporter (ASBT) [19]. The ileal bile acid binding protein 
(IBABP) facilitates the intracellular transport of bile acids across the enterocyte, and the 
bile acids are effluxed to the portal blood via organic solute transporter α and β (OSTα/ 
OSTβ) [20]. Other transporters like MRP2, MRP4 and MRP3 are known to be involved 
in the transport of bile acids at the apical membrane and basolateral membrane of the 
enterocytes, respectively [21].  
 The circulating bile acids in the portal blood are taken up by the hepatocytes 
through the basolateral membrane by Na+ dependent co-transporter system, NTCP 
[19,22]. It is estimated that 90% of the bile acid uptake is via Na+-taurocholate 
cotransporting polypeptide (NTCP) and to a lesser extent by organic anion transporting 
polypeptides (OATP1 and OATP4).  At the canalicular membrane of the hepatocytes, 
BSEP (bile salt export pump) plays a major role in the secretion of bile acids into the 
bile canaliculi whereas MRP2 (multidrug resistance associated protein-2) mediates 
secretion of bile acids along with other organic solutes [21,22]. The heterodimeric 
organic solute transporters (OSTα/ OSTβ), MRP3 and MRP4 mediate secretion of bile 
acids into the circulation at the basolateral membrane of the hepatocytes [19,20,23].   
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1.4. Bile acid receptors 
 The importance of bile acids as signaling molecules in the regulation of 
physiological function has gained attention with the discovery of receptors for bile acids. 
The most prominent and best-studied bile acid receptors are FXR and TGR5 (Figure 2).  
1.4.1. FXR 
 In 1999 three independent research groups reported that bile acids act as ligands 
for the farnesoid X receptor (FXR) [24-26]. The discovery of FXR was later followed by 
human steroid and xenobiotic receptor (SXR) and its rodent homolog pregnane X 
receptor (PXR), vitamin D receptor (VDR), and constitutive androstane receptor (CAR), 
all of which are bile acid activated nuclear receptors that are known to be functionally 
related [27-29].  
 Farnesoid X Receptor (FXR) or NR1H4, a member of the nuclear receptor 
superfamily was identified during the search for a new heterodimer that binds to the 
retinoid X receptor (RXR).  FXR, originally activated by farnesol was later identified as a 
receptor that is activated by bile acids in 1999. FXR is highly expressed in liver, 
intestine, kidneys and adrenal glands and is selectively activated by CDCA [24-26]. FXR 
was identified as a master regulator playing a pivotal role in the feedback regulation of 
bile acid synthesis by repressing CYP7A1, the rate-limiting enzyme of the synthetic 
pathway [7,9,17]. FXR activates the expression of the bile acid export transporters, 
multidrug resistance- associated protein 2 (MRP2) and bile salt export pump (BSEP) 
and simultaneously represses bile acid import to regulate bile acid transport [30,31].  
 
 
	  	   7	  
 
 
 
Figure 2. Schematic representation of the activation of TGR5 and FXR by bile 
acids. TGR5 is a plasma membrane G protein coupled receptor and FXR is a nuclear 
receptor that is activated by bile acids. The receptors are activated by both primary (CA 
and CDCA) and secondary bile acids (LCA and DCA). LCA is a potent activator of 
TGR5 while CDCA for FXR. 
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Thus, FXR functions as a sensor of metabolic signals and plays an important role in the 
regulation of bile acids synthesis and transport, lipid metabolism and glucose 
homeostasis [32-34].   
1.4.2. TGR5 
    Takeda G-protein coupled Receptor clone 5 (TGR5) also known as GPBAR1, M-
BAR or BG37 was first discovered in 2002 by two independent research groups in 
Japan [35,36]. TGR5 is encoded by a single exon gene that maps to chromosome 
position 1c3 in mice and to chromosome 2q35 in humans. The coding region of human 
TGR5 gene consisting of 993 bp encodes 330 amino acids and the protein shares 82, 
83, 86 and 90% homology with rat, mouse, bovine and rabbit respectively [37]. TGR5 is 
a member of the rhodopsin like (class A) subfamily of GPCRs and is ubiquitously 
expressed with varied degree of expression in different organs such as spleen, 
placenta, gallbladder, liver, kidney, small intestine, colon, heart, skeletal muscles, 
pancreas etc [38]. The bile acid receptor TGR5 is activated by different bile acids, with 
taurine-conjugated lithocholic acid (TLCA) being the potent agonist with an EC50 value 
of 0.33 µM. The other bile acids that activate TGR5 include LCA, DCA, CDCA and CA 
with EC50’s of 0.53, 1.01, 4.43 and 7.72 µM respectively [39,40]. In addition to their 
cognate receptors, bile acids are also known to modulate the activity of formyl-peptide 
receptors (FPR), muscarinic receptors and S1PR2 (Sphingosine-1 phosphate receptor 
2) [41,42]. Some of the steroids such as progesterone, androgen, estrogens, oxysterols, 
and pregnenolone also stimulate TGR5. However, the concentrations of these steroids 
required to activate TGR5 are much higher than the physiological concentration and are 
not considered as receptors for these steroid hormones in vivo [35].  
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1.5. Physiological significance of bile acids 
 In addition to their classical role in lipid digestion and absorption, bile acids are 
now known to play an important role in the regulation of different organ function by 
acting as endogenous ligands [38-40]. Bile acids via activation of its nuclear receptor, 
FXR or membrane receptor, TGR5 not only regulate their own synthesis and 
metabolism but also regulate glucose and lipid metabolism and energy homeostasis 
[9,16,42]. Thus bile acids activated signaling pathways serve as potential therapeutic 
targets for the treatment of various metabolic related diseases such as obesity, type 2 
diabetes, hyperlipidemia and atherosclerosis [15,38,43,44].  
1.5.1. Functions via FXR 
          Bile acids regulate their own synthesis by exerting a negative feedback 
mechanism. Activation of nuclear receptor FXR by bile acids inhibits CYP7A1, a key 
enzyme in the synthesis of bile acids [7,9]. In the liver, activation of FXR induces SHP 
(short heterodimer partner) expression. SHP exerts its inhibitory effect by interacting 
with LRH-1 (liver receptor homolog-1) and HNF4α (hepatocyte nuclear factor 4 alpha) 
and represses CYP7A1 gene expression [14]. In the intestine, bile acids activate FXR, 
which induces FGF19 (fibroblast growth factor 19) expression. The FGF19 released 
from the epithelial cells of small intestine circulates and bind to FGFR4 (fibroblast 
growth factor receptor 4) on the hepatocytes. The FGF19/FGFR4 signaling activates 
JNK (c-Jun NH2-terminal kinase) pathway that inhibits CYP7A1 gene transcription [7,9]. 
Activation of FXR also up regulates the expression of bile acid export transporters 
MRP2 and BSEP and down regulates NTCP, the bile acid import transporter. FXR also 
positively regulates the expression of the enzymes involved in the detoxification of bile 
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acids such as SULT2A1 and CYP3A4 [17]. Thus, activation of FXR regulates bile acid 
synthesis and transport and plays an important role in hepatoprotection [17,30,45].  
          Bile acids via hepatic FXR activation leads to decreased triglyceride synthesis 
and secretion and is an important regulator of lipid metabolism [31,32]. In addition to 
these, the role of FXR in glucose homeostasis via the regulation of gluconeogenesis 
and glycogenolysis is demonstrated [46]. The activation of FXR decreases 
gluconeogenesis and increases glycogen synthesis, the combined effect of which 
reduces hyperglycemia.  FXR also plays an important role in skeletal muscles and 
adipose tissue by increasing insulin sensitivity and is thus a therapeutic target for 
treating metabolic syndrome [31-34]. 
1.5.2. Functions via TGR5 
 Bile acids acting via TGR5 play an important role in the physiology of liver and 
gallbladder. In liver, TGR5 is expressed in the sinusoidal endothelial cells and the 
activation of which leads to the production of nitric oxide aiding in hepatic 
microcirculation, which also serves to be beneficial in the case of portal hypertension 
[47]. Bile acids inhibits LPS-induced cytokine expression in kupffer cells of the liver and 
therefore it is evident that there is an increase in the immunoreactivity by the activation 
of TGR5 in bile duct ligated rats (impaired bile flow and rise in cytokines) when 
compared to sham operated control rats [48,49]. In the cholangiocytes (epithelial cells of 
the bile duct), activation of TGR5 protects against lipid peroxidation and bile acid-
induced injury by exerting anti apoptotic and anti-inflammatory effects [50]. Bile acids 
also play a role in immunomodulation and regulate the production of cytokines by the 
activation of TGR5 in monocytes [51]. The gallbladder volume was increased in wild 
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type mice when compared to TGR5 knockout mice upon the administration of LCA or 
INT-777 demonstrating that activation of TGR5 stimulates gallbladder filling. TGR5 also 
causes relaxation in the gallbladder smooth muscles [38,52].  
 Bile acids in the gastrointestinal tract regulate gut motility. Luminal administration 
of bile acids inhibits gastric motility and small intestinal transit, and the effect is 
mediated by activation of TGR5 present on the inhibitory motor neurons that release 
nitric oxide [53]. Recent studies have shown that bile acids stimulate colonic peristalsis, 
facilitating normal transit and digestion [54,55]. Studies by Rajagopal et al., [56] have 
showed that bile acid induced TGR5 activation causes gastric smooth muscle 
relaxation. Activation of TGR5 in primary spinal afferent and sensory neurons is known 
to mediate itch and analgesia, a mechanism, which contributes to pruritus and painless 
jaundice in patients with cholestatic liver disease [57].  
 The study of the role of TGR5 in the regulation of energy expenditure is gaining 
prime importance as obesity has become a major concern and also as it is highly 
associated with type II diabetes, which is a threat to the public health. Increasing 
physical exercise and reducing calorie intake are the first line of treatment for individuals 
with obesity. In this regard, bile acid induced TGR5 activation caused a significant 
reduction in body weight.  Studies by Watanabe et al., [58] and Maruyama et al., [59] 
have showed that administration of cholic acid to the mice on a high fat diet caused 
reduction in the body weight gain and TGR5-/- mice when fed with high fat diet became 
obese when compared to wild type mice. Skeletal muscles and brown adipose tissues 
are the most important thermogenic sites where activation of TGR5 regulates energy 
metabolism [60]. The possible mechanisms involved in this process are the upregulation 
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of type 2 iodothyronine deiodinase (D2) expression as well as peroxisome proliferator-
activated receptor-γ coactivator- 1 α  (PGC-1α). It is important to note that these 
molecular events are purely TGR5 dependent and FXR independent [58]. The 
expression of D2 and PGC-1α  are regulated through the cAMP-PKA (protein kinase A) 
dependent pathway. Both humans and mice possess cAMP responsive elements (CRE) 
in the promoter regions of D2 and PGC-1α  [61]. The activation of D2, mediated via 
TGR5 leads to conversion of inactive thyroxine (T4) to active 3,5,3- tri iodothyronine 
(T3), which binds to the thyroid hormone receptor (THR) resulting in the transcriptional 
activation of key genes of energy expenditure such as uncoupling proteins (UCP-1, 2 or 
3) [62,63]. Similarly increased PGC-1α induces expression of uncoupling proteins.  
Activation of uncoupling proteins leads to dissipation of the proton gradient and 
uncoupling of oxidative phosphorylation generating more heat [64]. This is consistent 
with the impairment of mitochondrial function in the skeletal muscle and brown adipose 
tissue of PGC-1α  -/- mice [62]. The transcriptional co-activator PGC-1α binds to and 
increases the activity of PPARs to regulate fatty acid β-oxidation and is evident by the 
knockout and over-expression of PPARγ studies. PGC-1α also modulates the activity of 
a number of transcription factors that can increase the expression of proteins involved in 
fatty acid β-oxidation, the TCA cycle, and the electron transport chain [61]. 
 Bile acids play an important role in glucose homeostasis. Studies have 
demonstrated that bile acids via activation of TGR5 induce GLP-1 secretion from the 
intestinal L cells [65]. INT-777, a specific TGR5 agonist stimulates GLP-1 secretion in 
mouse enteroendocrine cells, STC-1 as well as in human intestinal NCI-H716 cells [66]. 
GLP-1 is known to regulate postprandial glycemic response by stimulating glucose 
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dependent insulin secretion from the pancreatic β cells and inhibition of glucagon 
secretion from pancreatic α cells [67]. TGR5, in addition, to inducing insulin secretion 
also increases insulin sensitivity. Insulin induced by TGR5 increases glucose uptake in 
the skeletal muscle as well as in adipose tissue [62,63]. The possible mechanisms 
involve increase in GLUT-4 expression, an insulin regulated glucose transporter, 
leading to the uptake of glucose (postprandial glycemic control) and its oxidative 
phosphorylation [66]. Thus the involvement of TGR5 in glucose homeostasis was 
investigated in vivo using both gain of function and loss of function genetic approaches, 
and was further elucidated by the treatment with a selective TGR5 ligand and or INT-
777, a specific TGR5 ligand [66]. 
 Although the role of TGR5 in glucose homeostasis via release of GLP-1 from 
enteroendocrine cells is well established, the direct effect of bile acids on endocrine 
cells of pancreas is unclear (Figure 3).  
1.6. Pancreas 
         The Pancreas is an organ that lies in an oblique and transverse position in the 
upper left abdomen. In an adult, the pancreas is about 15 to 20 cm long and weighs 
about 75 to 100 g [68,69]. The pancreas is a dual function gland with both exocrine and 
endocrine functions [70].  
1.6.1. Exocrine pancreas 
      The exocrine pancreas comprises 85-90% of the total pancreatic mass. The two 
major components of the exocrine pancreas are the acinar cells that are arranged into 
acini and the ductal system that carries the secretion into the duodenum [71].  
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Figure 3. A diagrammatic representation of the functional significance of TGR5. 
TGR5 is expressed in different tissues and is involved in the regulation of energy 
metabolism and glucose homeostasis. Bile acids via TGR5 modulate immune response 
and regulate gut motility. In the skeletal muscle and adipose tissue, TGR5 activation 
increases energy expenditure and insulin sensitivity. Activation of TGR5 in the intestinal 
L cells stimulates GLP-1 secretion, an incretin hormone that potentiates insulin 
secretion from pancreatic β cells. However the direct effect of bile acids via activation of 
TGR5 in the regulation of pancreatic β cell function is unknown. Adapted from Intercept 
Pharmaceuticals. 
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The exocrine pancreas functions to produce pancreatic enzymes critical to digestion 
and the enzymes include proteases, amylases, lipases, and nucleases with the function 
of breaking down specific components of the chime released from the stomach into the 
duodenum. In addition, bicarbonates are secreted from the epithelial cells lining these 
pancreatic ducts [70,71]. 
1.6.2. Endocrine pancreas 
 The endocrine portion of the pancreas comprises small clusters of cells called 
islets of Langerhans or simply termed islets. The islets (comprising only 1-2% of the 
pancreatic mass) are found scattered throughout the pancreas. In a normal adult 
pancreas there are nearly 1 million islets and each islet is known to contain 1000 to 
3000 cells [68,69]. The Pancreatic islets consist of five different cell types, each of 
which produces a different hormone. Alpha (α) cells secrete glucagon, beta (β) cells 
secrete insulin, delta (δ) cells secrete somatostatin, epsilon (ε) cells secrete ghrelin, and 
PP cells that secrete polypeptides. The islets are highly vascularized by capillary 
network and innervated by various nerve fibers [72]. The capillaries within the islets are 
fenestrated facilitating secreted hormone into the circulation [73]. The cytoarchitecture 
of pancreatic islets differs between species [74]. In mouse islets, more than 70% of the 
cells are β cells forming the core and < 20% are α cells that are towards the periphery 
along with δ delta cells (< 5%). In contrast, human islets are composed of ~60% of β 
cells and ~30% of α cells. The β cells are intermingled with α and δ cells (<5%) in the 
human islets [75].  
 The secretion of hormones from the pancreatic islet is complex and highly 
regulated. Interplay of neural signals, blood flow patterns, autocrine and paracrine effect 
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are known to control islet secretion [68,73,76]. The paracrine signaling within the islets 
is an important regulator of pancreatic hormone release [77]. For instance, insulin 
stimulates its own release but inhibits the release of glucagon from α cells. Glucagon 
inhibits its own release but stimulates insulin release from β cells. Somatostatin 
released from δ cells inhibits the release of both insulin and glucagon [78,79]. Thus 
there exist a co-ordination in the intraislet regulation of hormone secretion within 
pancreatic islets [68,76].   
1.7. GPCRs and Pancreatic islets 
      Although glucose is the predominant trigger for insulin secretion from pancreatic 
β cells [80], it is also known that the effect of glucose is modulated by activation of G 
protein coupled receptors expressed on β cells which may either have a positive or 
negative effect on insulin secretion depending on the intracellular signaling pathways 
[81]. Generally activation of receptors coupled to Gαs or Gαq stimulate insulin secretion 
whereas activation receptors coupled to Gαi inhibit insulin secretion.  Table 1 lists some 
of the GPCRs expressed on the pancreatic β cells that are known to effect insulin 
secretion. The characterization of GPCR in pancreatic islets are largely focused on the 
β cells, and less is known about the role of GPCR in α cells or δ cells [82]. To date, 
GLP-1 based therapy represents one of the best-studied and clinically successful 
therapeutic strategy in targeting islet GPCR [83]. Thus GPCRs are potential therapeutic 
targets for the treatment of islet dysfunction or diabetes therapy due to their gaining 
importance in the regulation of islet function [81-83].  
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1.7.1. GLP-1 receptor 
     GLP-1 receptors belonging to class B family of GPCRs also include receptors for 
glucagon and GIP [84]. GLP-1 receptor (GLP-1R) was first cloned from rat pancreatic 
islets and is known that rat and human GLP-1R possess 95% amino acid homology and 
is a 64 kDa protein. GLP-1R is widely expressed in pancreatic islets as well as in other 
tissues including brain, heart, kidney, lung and gastrointestinal tract [85] and to date, 
only a single GLP-1 receptor has been identified [84,85]. Activation of GLP-1R is 
coupled to Gαs with subsequent activation of adenylyl cyclase and production of cAMP. 
Other signaling pathways such as MAP kinase, PI3 kinase and PKB pathways are also 
known to be activated by GLP-1 [86].  
1.7.2. Physiological effects of GLP-1 
     Glucagon like peptide-1 (GLP-1) is a 30 amino acid peptide hormone secreted 
from the intestinal L cells located predominantly in the ileum and colon [87]. GLP-1 is a 
product of the proglucagon gene along with the other cleaved peptides in the 
enteroendocrine L cells, which includes GLP-2 and small fragment peptides like 
glicentin, oxytomodulin and two intervening peptides (IP-1 and IP-2).  Proglucagon gene 
is cleaved to glucagon in α cells of the pancreas [84]. The amino acid sequence of GLP-
1 is highly conserved between the species and is identical in all mammals [85]. GLP-1 is 
secreted in two bioactive forms, GLP-1 (7-37) and GLP-1 (7-36) amide, both of which 
have same half-life and identical activity [88]. Circulating levels of GLP-1 are very low at 
fasting state and rapidly increase following meal ingestion within 10 to 15 minutes [89]. 
Following its secretion into the blood, GLP-1 is rapidly degraded by the enzyme 
dipeptidyl peptidase- IV (DPP-IV) and the half-life of GLP-1 is less than 5 minutes.  
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     GLP-1, an incretin hormone stimulates insulin secretion from the pancreatic β 
cells and the effect of GLP-1 on insulin secretion is strictly glucose dependent [90]. In 
addition to insulin secretion, GLP-1 is also shown to up regulate insulin gene 
transcription. The treatment of GLP-1 in isolated β cells increases insulin transcription 
through stabilization of insulin transcript and also by activation of the transcription factor 
PDX-1 [67]. GLP-1 is known to have trophic effects on pancreatic β cell mass as it 
stimulates β cell proliferation and β cell neogenesis in rat and human pancreatic duct 
[89]. This chronic effect of GLP-1 involving inhibition of apoptosis and stimulation of islet 
neogenesis has gained major interest in the treatment of diabetes [90]. The 
mechanisms underlying the effects of GLP-1 on islet regeneration involves upregulation 
of PDX-1 gene expression, PI3K activity and also transactivation of epidermal growth 
factor receptor [86,87]. The other key and specific effects of GLP-1 involve its inhibitory 
action on glucagon secretion from pancreatic α cells. This inhibitory effect of GLP-1 on 
glucagon secretion also contributes to an important mechanism for regulating elevated 
blood glucose levels in patients with type 2 diabetes [84,90].  
     In addition to the above-mentioned effects of GLP-1 on pancreas, it is also 
known to regulate gastrointestinal secretion and motility and has an inhibitory effect on 
gastric motility [85,87]. GLP-1 is also shown to reduce caloric intake by regulating 
appetite, the effects of which are mediated by the central nervous system. GLP-1 also 
increases insulin sensitivity in the peripheral tissues by improving insulin signaling and 
reducing gluconeogenesis [91,92].  
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1.8. Bile acids and GLP-1 
    Studies have demonstrated that bile acids have beneficial effects on glucose 
metabolism by improving postprandial glycemic control and insulin sensitivity and this is 
mainly associated with the activation of TGR5 by bile acids [58,63,66]. It was first 
reported by Katsuma et al., [65] that bile acids induce GLP-1 release in cultured mouse 
enteroendocrine STC-1 cells, whereas silencing of TGR5 using shRNA prevented the 
secretion of GLP-1 illustrating the involvement of TGR5 in bile acid induced response. 
GLP-1 is secreted from the enteroendocrine L cells, which are predominantly localized 
in the distal ileum and colon. Although the secretion of GLP-1 is stimulated by ingestion 
of food (carbohydrates, proteins and fats) and by neural signals, the major stimulus for 
the secretion of GLP-1 is the presence of nutrients, mainly fat and bile acids in the distal 
ileum [84,87]. This is correlated with the high levels of bile acid receptor TGR5 
expression in the distal ileum and colon [35,36]. GLP-1 being an incretin hormone 
potentiates insulin secretion by binding to its receptors on the pancreatic β cells [88,89]. 
Dr. Schoonjan’s group has also shown that TGR5 transgenic mice of obese and insulin 
resistant models are more glucose tolerant when compared to TGR5-/- mice, which have 
impaired glucose clearance [66]. The same group has also shown the release of GLP-1 
from both STC-1 cells and human intestinal NCI-H716 cells by the activation of TGR5 
using INT-777 (a specific TGR5 ligand). In this way, insulin secretion is indirectly 
regulated by TGR5 mediated GLP-1 release. However the expression and functional 
significance of TGR5 receptors in the pancreatic islets is not known and hence the 
focus of our study was to determine the direct effect of bile acids on pancreatic islets.  
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Table 1: GPCRs and their effect on insulin secretion in pancreatic β cells (modified from 
Ahren B, 2009) 
RECEPTOR	   FULL	  NAME	   LIGAND	   G	  
PROTEIN	  
EFFECT	  ON	  
INSULIN	  
SECRETION	  
GLP-1R Glucagon like peptide- 1 
receptor 
 
GLP-1 Gs Stimulatory 
 
GIPR 
 
Glucose-dependent 
insulinotrophic polypeptide 
receptor 
 
GIP Gs Stimulatory 
 
GPR40 
and 
GPR120 
 
G protein-coupled receptor 40 
and  
G protein-coupled receptor 120 
Long chain 
fatty acids 
 
Gq Stimulatory 
 
GPR41 
and 
GPR43 
 
G protein-coupled receptor 41 
and 
G protein-coupled receptor 43 
Short chain 
fatty acids 
 
Gq Stimulatory 
 
GCGR 
 
Glucagon receptor Glucagon Gs Stimulatory 
 
T1R1/T1R3 Amino acid taste receptor Amino acids Gq Stimulatory 
 
GSHR 
 
Ghrelin receptor Ghrelin Gi Inhibitory 
β2 
 
β2 adrenergic 
 
Epinephrine Gs Stimulatory 
 
α2 
 
α2 adrenergic Norepinephri
ne 
Gi Inhibitory 
MT1 
 
Melatonin receptor 1 Melatonin Gi Inhibitory 
M3 
 
Muscarinic receptor 3 Acetylcholine Gq Stimulatory 
 
CB1 
 
Cannabinoid receptor 1 Cannabinoids Gi Inhibitory 
SSTR2 
 
Somatostatin receptor 2 Somatostatin Gi Inhibitory 
CCK1R 
 
Cholecystokinin 1 receptor Cholecystoki
nin 
Gq Stimulatory 
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CHAPTER	  2	  
REGULATION	  OF	  INSULIN	  SECRETION	  IN	  PANCREATIC	  β	  CELLS	  BY	  	  
THE	  BILE	  ACID	  RECEPTOR	  TGR5	  
	  
	  
2.1 Introduction 
 Bile acids acting via the nuclear receptor farnesoid-X-receptor (FXR) and the 
membrane GPCR (TGR5) are known to play an important role in the regulation of 
cholesterol and triglyceride metabolism, insulin sensitivity, the intestinal endocrine 
response to meals and energy homeostasis [31,34,38,40,63].  Studies by Katsuma et 
al., have shown the role of TGR5 in mediating the release of incretins, glucagon-like 
peptide-1 (GLP-1) and GLP-2 from the intestinal enteroendocrine cells [65]. Both GLP-1 
and GLP-2 promote insulin secretion from pancreatic β cells [88,89].   
 Insulin plays an important role in the regulation of glucose metabolism [93,94]. It 
is a peptide hormone composed of 51 amino acids with two polypeptide chains, the A- 
and B-chains that are linked together by disulphide bonds [68]. Insulin secretion is a 
highly regulated dynamic process and is modulated by nutrient status, neural, endocrine 
and paracrine factors [95]. Pancreatic β cells express receptors for various endogenous 
ligands that integrate the signals to modulate the synthesis and secretion of insulin to 
maintain glucose homeostasis under basal and post-prandial conditions. Insulin
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promotes energy use as well as storage and thus decreases circulating blood glucose 
levels. The 3 major sites of insulin action are liver, skeletal muscle and adipose tissue 
[96]. Insulin upon binding to its cognate receptor (tyrosine kinase receptor) induces 
signal transduction cascade, which promotes the uptake of glucose by the glucose 
transporter (GLUT4) into the cells [93]. In liver, insulin promotes synthesis and storage 
of glycogen and reduces hepatic glucose production by inhibiting gluconeogenesis and 
glycogenolysis [97]. In skeletal muscle, insulin-stimulated glucose uptake accounts for 
energy production and in the adipose tissue, insulin increases triglyceride synthesis 
facilitating fat storage in the cells and also inhibits fatty acid breakdown [96].  
 The predominant trigger for insulin secretion in β cells is increased blood glucose 
level. Thus glucose-stimulated insulin secretion (GSIS) is a process coordinated by the 
uptake of glucose from the β cells, metabolism and Ca2+ triggered insulin exocytosis 
[98]. The β cells take up glucose by the glucose transporter 2 (GLUT-2), the metabolism 
of which increases the ATP:ADP ratio, causing the ATP sensitive K+ channels to close 
and thereby induce membrane depolarization. This in turn opens the voltage gated Ca2+ 
channels to increase the influx of Ca2+ and elicit insulin release. The effect of glucose is 
also modulated by the activation of GPCRs, which optimize glucose-stimulated insulin 
secretion (Table 1). Pancreatic β cells also express several G-protein coupled receptors 
(GPCRs) and these include receptors for peptides (GLP-1, GIP, glucagon and 
somatostatin), amino acids (T1Rs), free fatty acids (GPR40, GPR41, GPR43, GPR84, 
GPR120) and acetylcholine (muscarinic m3 receptors). Activation of GPCRs coupled to 
Gs or Gq stimulates insulin secretion whereas activation of those coupled to Gi inhibits 
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insulin secretion [81,99-103]. However the role of bile acids in the regulation of insulin 
secretion in the pancreatic β cells via activation of TGR5 by bile acids is unknown.   
 Bile acids that are released in response to meal are found in significant amount 
in the systemic circulation. Under fasting conditions, circulating bile acids are less than 
5 µM whereas postprandial levels rise up to 15 µM [4]. We therefore postulated that bile 
acids acting via its membrane receptor, TGR5 could stimulate insulin secretion from 
pancreatic β cells. 
 
2.2. Materials and Methods 
2.2.1. Materials 
 Oleanolic acid (OA) and lithocholic acid (LCA) were obtained from Sigma-Aldrich 
(St Louis, MO) and INT-777 (S-EMCA: 6α-Ethyl-23(S)-methylcholic Acid) was a 
generous gift from Intercept Pharmaceuticals. [35S] GTPγS, myo-[3H] inositol and 
[125I]cAMP were obtained from Perkin Elmer (Boston, MA); polyclonal antibody to TGR5 
was purchased from Abcam (Cambridge, MA); antibodies to Gαs, Gαq, Gαi1, Gαi2 and 
Gαi3, and NF449 were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA); 
ultrasensitive mouse insulin ELISA kit was obtained from Crystal Chem. Inc. (Downers 
Grove, IL); ultrasensitive human insulin ELISA kit was purchased from Mercodia 
(Uppsala, Sweden). Collagenase P was obtained from Roche Diagnostics (Indianapolis, 
IN); Fura 2-AM, HEPES and RPMI were obtained from Invitrogen (Eugene, OR); 
U73122 and Myristoylated PKI were obtained from Calbiochem (La Jolla, CA); western 
blotting and chromatography materials were obtained from Bio-Rad Laboratories 
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(Hercules, CA). RNeasy Plus universal Mini kit and Taq PCR core kit were obtained 
from Qiagen (Venlo, Netherland); PCR reagents were obtained from Applied 
Biosystems (Foster city, CA). Dulbecco’s Modified Eagle Medium (DMEM), 2-
mercaptoethanol, 8-pCPT-2'-O-Me-cAMP, BAPTA-AM, Histopaque (10771 and 11191) 
and all other reagents were obtained from Sigma (St Louis, MO).  
Wild type C57BL/6J mice were purchased from Jackson laboratories (Ban 
Harbor, ME) and euthanized with CO2. The animals were housed in the animal facility 
administered by the Division of Animal Resources, Virginia Commonwealth University. 
All procedures were conducted in accordance with the institutional Animal Care and 
Use Committee of the Virginia Commonwealth University. 
2.2.2. Cell culture 
 The insulin secreting mouse pancreatic beta (β) cell line, MIN6 cells were 
cultured in DMEM containing L-glutamine, sodium carbonate and 2.5 mM 2-
mercaptoethanol. The insulin secreting rat pancreatic β cell lines, INS-1 and 823/13 
cells (a kind gift from Dr. Christopher Newgard, Duke University) were cultured in RPMI 
containing Hepes, L-glutamine, sodium pyruvate and 2-mercaptoethanol. All the media 
were supplemented with 10% fetal bovine serum and 100U/ml pencillin-streptomycin 
and the cells were incubated at 37°C in 5% CO2. 
2.2.3. Isolation and maintenance of mouse islets 
      Pancreatic islets from mice were isolated by sequential enzyme digestion of 
pancreas, filtration and centrifugation as described previously [104]. The mice were 
euthanized using CO2. The abdominal surface was wetted with 70% ethanol and 
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opened with standard pair of scissors in a V shape starting from the lower abdomen and 
extending to the lateral portions of the diaphragm so that the organs in the peritoneal 
cavity are well exposed. The common bile duct was clamped off near the junction with 
the small intestine using John Hopkin’s Bulldog clamp. About 4-5 ml of collagenase P 
solution (Collagenase P was dissolved in G solution- 1X HBSS, 0.35 mM sodium 
bicarbonate and 1% BSA) was injected into the pancreas through the common bile duct 
(Figure 4A). The inflated pancreas was then carefully removed and incubated in 370C 
water bath for 5-9 minutes. Following digestion, the pancreatic tissue was subjected to 
centrifugation and filtration so as to remove the undigested tissue. Density gradient 
centrifugation was carried out using histopaque 1110 solution for 20 min at 1200 rpm to 
separate acinar tissues from the islets. The supernatant (containing the islets) was 
collected and washed twice with G solution by centrifuging at 1200 rpm for 4 min. 
Solution containing the islets was then passed through an inverted 70 µm sterile strainer 
or filter to remove the remaining acinar tissue and maintained in RPMI-1640 medium 
supplemented with 10% FBS and 100U/ml pencillin-streptomycin and incubated at 37°C 
in 5% CO2. The islets are then handpicked under the microscope and counted prior to 
experimentation (Figure 4B and 4C).  
      Human islets were obtained from the National Disease Research Interchange 
(NDRI), Philadelphia, PA. 
2.2.4. RNA Isolation and RT-PCR analysis 
      Total RNA was isolated from cells (MIN6, INS-1 and 823/13) and mouse and 
human islets using RNeasy Plus Universal Mini Kit (Qiagen) following manufacturer’s 
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instructions. 1 µg of the total RNA was reverse transcribed using high capacity cDNA 
reverse transcriptase kit (Applied Biosystems) with random primers in a 20 µl reaction 
volume. Conventional PCR was performed on 2 µl of cDNA using Taq PCR core kit 
(Qiagen) in a final volume of 20 µl using specific primers (Table 1). The amplified PCR 
products were analyzed on 2% agarose gel containing ethidium bromide using Gel 
DocTM EZ imager.  
      Real time PCR was carried out using StepOneTM Real-Time PCR system (Applied 
Biosystems). Quantitative real-time PCR was performed for TGR5 (Mm 04212121_s1)	  
with TaqMan probes mixed with TaqMan PCR Master-Mix for 40 cycles (950C for 15 
sec, 600 C for 1 min) using 2-5 ng of cDNA in a 20 µl reaction volume. Quantitative real- 
time PCR of the same sample was performed for β-actin (Mm 00607939_s1) expression 
as internal control for normalization.	  Each sample in the real time PCR reactions was 
performed in triplicates and no template control was also preformed to confirm the 
efficiency and lack of primer dimer formation in the reactions.  
      Quantification of gene expression was done using relative quantification method. 
In this method, the PCR signal (cycle threshold- Ct value) of the target transcript in a 
treatment group to that of another sample such as untreated control was compared. The 
difference in Ct values between TGR5 and β Actin was calculated as ΔCt values. ΔCt 
values of treated samples were subtracted from ΔCt values of control samples to obtain 
ΔΔCt values. Finally the relative fold change in the gene expression was calculated as 
2-ΔΔCt.  
ΔΔCt= (Ct Target- Ct Endogenous control) Treatment minus (Ct Target- Ct Endogenous control) Control 
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Relative gene expression (Fold Change)= 2-ΔΔCt 
2.2.5. Western blot analysis 
      The cells were solubilized in RIPA buffer (Sigma) containing protease inhibitor 
cocktail (104 mM AEBSF, 80 µM Aprotinin, 4 mM Bestatin, 1.4 mM E-64, 2 mM 
Leupeptin, 1.5 mM Pepstatin A). The supernatant was collected after centrifuging the 
lysate at 10000g for 15 min at 40C and the protein concentration was determined by DC 
protein assay kit from Bio-Rad. Equivalent amounts of proteins were resolved by SDS-
PAGE and transferred onto a nitrocellulose membrane. Blots were blocked in 5% non 
fat dry milk + tris buffered saline with 0.1% tween-20 (TBST) for 1 hour and then 
incubated with various primary antibodies in 5% non fat dry milk + TBST or 5% BSA + 
TBST for overnight at 40C. The blots were washed with TBST three times for 5 min and 
then incubated for 1 hour at room temperature with horseradish peroxidase conjugated 
corresponding secondary antibodies in 5% non fat dry milk + TBST. The washing steps 
were repeated as before and the immunoreactive proteins were visualized using 
SuperSignal West Pico chemiluminiscent substrate kit (Pierce, IL).  
Western blot images were scanned and analyzed with ImageJ software for 
densitometric measurements. The average intensity obtained for each band was 
normalized to its respective band of β-actin. The band intensity was then presented as 
relative fold changes compared with the corresponding control.  
2.2.6. Assay for identification of activated G proteins 
     MIN6 cells were homogenized and the crude membranes were solubilized 
following the procedure as described previously [105]. Membranes isolated from MIN6 
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cells were incubated with 60 nM [35S] GTPγS containing 10 mM Hepes (pH 7.4), 0.1 
mM EDTA and 10 mM MgCl2 for 30 min at 37°C in the presence or absence of OA (10 
µM) and INT-777 (25 µM).  The reaction was stopped by adding 10 volumes of 100 mM 
Tris/HCl (pH 8) containing 10 mM MgCl2, 100 mM NaCl and 20 µM GTP and was then 
incubated in wells precoated with specific antibodies to Gαs, Gαq, Gαi1, Gαi2 and Gαi3 for 
2 h in ice.  After incubation, the solution was discarded and the wells were washed with 
PBS containing 0.05% Tween followed by solubilization with 0.1N NaOH. The 
radioactivity in each well was counted by liquid scintillation and expressed in cpm/mg 
protein. 
2.2.7. Assay for adenylyl cyclase activity 
 MIN6 cells were treated with 100 mM IBMX and TGR5 ligands (OA or INT-777, 
25 µM), the reaction was stopped with 6% Trichloroacetic acid and the suspension was 
centrifuged at 2000g for 15 min at 40C. The supernatant was extracted with water 
saturated diethyl ether and lyophilized. The samples were reconstituted with 500 ul of 
50 mM sodium acetate and cAMP was measured by radioimmunoassay as described 
previously [106]. 100 µl of aliquots were taken from each sample and acetylated with 
tetraethyl ammonium/acetic anhydride (2:1 v/v) for 30 min. After overnight incubation, 2 
ml of 50 mM sodium acetate was added and centrifuged. The samples were decanted 
by discarding the supernatant and the antigen-antibody complex (pellet) was counted in 
the gamma counter. The data was used to construct a standard curve from which the 
values of the unknowns were determined. cAMP levels were expressed as percent 
increase above basal levels.  
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2.2.8. Assay for phosphoinoside (PI) hydrolysis  
 MIN6 cells were labeled with myo-[3H] inositol (0.5 µCi/ml) in DMEM medium for 
24 h. After 24 h, cells were washed with PBS and treated with OA, INT-777, NF449 (a 
selective Gαs inhibitor), a selective Epac ligand (8-pCPT-2'-O-Me-cAMP) or U73122 (PI 
hydrolysis inhibitor) for 1 min. The reaction was terminated using 940 ul of Chloroform-
methanol-HCl (50:100:1 v/v) and to the samples extracted, 340 ul of chloroform and 340 
ul of water was added and centrifuged at 5,000 rpm for 10 min as described previously 
[107]. The upper aqueous phase was applied to the column prepared with Dowex AG-
50W-X8 resin and water (1:1) and washed with 5 mM sodium tetraborate/60 mM 
ammonium formate solution. The [3H] inositol triphosphate was eluted with 0.8 M 
ammonium formate plus 0.1 M formic acid. Radioactivity was determined by liquid-
scintillation counting and the result was expressed as percent increase above basal. 
2.2.9. Measurement of intracellular calcium 
 MIN6 cells cultured on glass cover slips, and mouse and human islets were 
washed with PBS and then loaded with 5 µM fura2-AM in HBSS buffer containing 3 mM 
glucose for 2 h at room temperature. Clusters of cells were selected for imaging and 
visualized as described previously [108]. The cells were visualized through the 40X 
objective of Zeiss Axioskop 2 plus upright fluorescence microscope and imaged with a 
set up consisting of a charge coupled device camera (Imago, TILL photonics) attached 
to an image intensifier. The cells were alternatively excited at 340 nm and 380 nm and 
the increase in intracellular calcium by the TGR5 ligands (OA or LCA) was measured by 
determining the ratio of the fluorescence of fura-2 at 340 and 380 nm excitation.  
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2.2.10. Measurement of Insulin secretion 
     MIN6 cells were plated at a density of 5 x 105 cells in 24-well plates with DMEM 
and cultured until confluent. The cells were washed and incubated in HBSS (114 mM 
NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.16 mM MgSO4, 20 mM HEPES, 2.5 mM CaCl2, 
25.5 mM NaHCO3, pH 7.2, 0.1% BSA) containing 3 mM glucose for 2 h at 370C.  Cells 
were then treated for 30 min in HBSS containing 3 mM (basal) or 25 mM glucose 
(stimulated) with or without OA, INT-777 or LCA.  The supernatants were collected and 
assayed for insulin using ELISA kit.  For insulin secretion from mouse islets (20-25 
islets/condition) or human islets (15-20 islets/condition), the islets were incubated at 
370C for 2 h in HBSS with 3mM glucose.  The same procedure as described above was 
followed. 
2.2.11. Statistical Analysis 
 Results were calculated as means ± SEM and the experiments were performed 
at least three times. The experiments were performed on islets isolated from different 
animals. Statistical significance was analyzed using Student’s t-test for paired and 
unpaired values. GraphPad Prism software was used for all statistical analyses and p 
values < 0.05 were considered significant. 
 
2.3. Results 
2.3.1. Expression of TGR5 in human and murine pancreatic islets and in 
pancreatic β cells 
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 Expression of TGR5 mRNA was detected in all three pancreatic β cell lines 
(MIN6, INS1 and 823/13) by qRT-PCR. Expression was 11.8 fold higher in MIN6 cells 
compared to INS1 and 2.5 fold higher compared to 823/13 cells (Figure 5).  RT-PCR 
analysis of RNA from islets of human and mice using specific primers demonstrated 
amplification of a PCR product of predicted size in both human islets (277 bp) and 
mouse islets (Figures 6A and 6B). The results suggest expression of TGR5 receptors 
in human and mouse islets.  
 Further confirmation for the expression of TGR5 receptors was obtained by 
western blot analysis using selective antibody to TGR5. The results demonstrated the 
expression of TGR5 receptor of predicted size (35 kDa) in the homogenates isolated 
from both MIN6 and mouse islets (Figure 6C).  
2.3.2. Stimulation of insulin secretion by TGR5 ligands 
 To investigate the role of TGR5 in insulin secretion, we examined whether basal 
(3 mM glucose) or stimulated (25 mM glucose) insulin secretion would be modulated by 
the activation of TGR5 receptors. The treatment of MIN6 cells with the selective TGR5 
ligand, OA stimulated insulin secretion in a dose dependent (10-50 µM) manner both at 
3 mM glucose (10 µM- 1.6±0.09, 30 µM- 2.2±0.16, 50 µM- 3.7±0.37 fold increase above 
3 mM glucose basal levels 32.2±1.8 ng/ml) and 25 mM glucose (10 µM- 1.2±0.03, 30 
µM- 2±0.08, 50 µM- 3.2±0.07 fold increase above 25 mM glucose basal levels 64.4±1.1 
ng/ml) conditions (Figure 7).  Consistent with the stimulatory effect of OA, the natural 
bile acid, lithocholic acid (LCA, 10 µM) also augmented both basal (1.5±0.09 fold 
increase) and stimulated (1.1±0.03 fold increase) insulin secretion (Figure 8).  
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 Treatment of mouse pancreatic islets with OA significantly stimulated both basal 
and stimulated insulin secretion (1.9±0.15 fold increase above 3 mM glucose basal 
levels 4.5±0.4 ng/ml; 1.5± 0.07 fold increase above 25 mM glucose basal levels 
10.3±0.1 ng/ml). Similar results were obtained when the islets were treated with the 
specific TGR5 agonist, INT-777 (1.6±0.1 fold increase above 3 mM glucose basal levels 
and 1.6±0.02 fold increase above 25 mM glucose basal levels) or natural bile acid LCA 
(1.5±0.21 fold increase above 3 mM glucose basal levels and 1.4±0.2 fold increase 
above 25 mM glucose basal levels). It is noteworthy that the extent of increase was 
similar with all three ligands used at the concentration of 25 µM each (Figure 9). 
 Treatment of human islets with 25 µM OA, INT-777 or LCA also caused an 
increase in insulin secretion at both basal and stimulated conditions: OA (2.4±0.28 fold 
increase above 3 mM glucose basal levels 2.7±0.2 ng/ml; 1.8±0.11 fold increase above 
25 mM glucose basal levels 6.05±0.1 ng/ml); INT-777 (2±0.22 fold increase above 3 
mM glucose basal levels and 1.6±0.05 fold increase above 25 mM glucose basal 
levels); and LCA (2.3±0.37 fold increase above 3 mM glucose basal levels and 1.5±0.08 
fold increase above 25 mM glucose basal levels) (Figure 10). 
2.3.3. Signaling mechanisms involved in TGR5-mediated insulin secretion in 
pancreatic β cells 
 After demonstrating the expression of TGR5 in β cells and secretion of insulin in 
response to TGR5 ligands, further studies were designed to examine the signaling 
pathways activated by TGR5 receptors to mediate insulin secretion. Biochemical 
approaches such as G protein activation, adenylyl cyclase activity and PI hydrolysis, 
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and intracellular Ca2+ were done in both MIN6 cells and islets from mouse and human. 
In addition, insulin secretion in response to TGR5 ligands was measured in the 
presence or absence of various inhibitors that block different steps in the signaling 
pathways.   
2.3.3.1. Activation of Gαs by TGR5 selective ligands 
 Incubation of MIN6 cell membranes with OA (Figure 11) or INT-777 (Figure 12) 
caused a significant increase in the binding of [35S]GTPγS selectively to Gαs (OA- 
20252±389 cpm/mg protein; 309±10.86% increase and INT-777- 19267±483 cpm/mg 
protein; 289±12.27% increase above basal levels 4957±38 cpm/mg protein), but not to 
Gαq, Gαi1, Gαi2 or Gαi3. These results suggest that TGR5 receptors are preferentially 
coupled to the activation of Gαs in pancreatic β cells.  
2.3.3.2. Activation of adenylyl cyclase by TGR5 selective ligands 
 Consistent with the activation of Gαs proteins, incubation of MIN6 cells with 25 
µM, OA or INT-777 caused stimulation of adenylyl cyclase resulting in an increase in 
cAMP levels: OA- 56% increase in cAMP levels above basal levels (0.32 pmoles/ml); 
and INT-777- 75% increase in cAMP levels above basal levels (0.32 pmoles/ml) (Figure 
13). The results are consistent with the selective activation of Gαs/cAMP pathway by OA 
in enteroendocrine cells and gastric smooth muscle cells [56,109]. 
2.3.3.3. Activation of Epac (cAMP-dependent exchange factor) by TGR5 selective 
ligands 
 To examine whether OA-induced insulin secretion involves PKA-dependent or –
independent mechanism, insulin secretion in response to OA was measured in the 
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presence of myristoylated PKI, a selective PKA inhibitor (Figure 14). The OA-induced 
insulin secretion was not significantly inhibited by Myr-PKI (9±5% inhibition at 3 mM 
glucose basal or 22±6% inhibition at 25 mM glucose basal) suggesting the involvement 
of alternative pathway of cAMP, which is PKA-independent. The pathway could involve 
sequential activation of Epac (cAMP-dependent exchange factor), Epac-dependent 
stimulation of PLC-ε activity and release of intracellular Ca2+ (Figure 15). Consistent 
with the above notion, the selective Epac ligand, 8-pCPT-2'-O-Me-cAMP (1 µM) also 
increased both basal (2.2±0.09 fold increase above 3 mM glucose basal levels) and 
stimulated (2.4±0.14 fold increase above 25 mM glucose basal levels) insulin secretion 
(Figure 16). 
The studies are corroborated by identification of Epac2 and PLC- ε expression.  
RT-PCR analysis demonstrated the expression of Epac2 and PLC-ε mRNA in MIN6 
cells, and mouse and human islets (Figure 17). 
2.3.3.4. Activation of PI hydrolysis by TGR5 selective ligands 
 Previous studies in enteroendocrine L cells have shown that GLP-1 release by 
OA was mediated via Gs/Epac/PLC-ε/Ca2+ pathway [109]. Activation of a similar 
pathway was examined in pancreatic β cells by measurements of PI hydrolysis in 
response to TGR5 selective ligands, OA and INT-777 and an Epac selective ligand, 8-
pCPT-2'-O-Me-cAMP. Both OA (958±11.02 cpm/mg protein; 249±3.52% increase above 
basal levels 274±3.84 cpm/mg protein) and INT-777 (846±2.52 cpm/mg protein; 
209±4.64% increase above basal levels) caused a significant and similar increase in PI 
hydrolysis (Figure 18). The OA-induced increase in PI hydrolysis was blocked by the 
C	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selective PI hydrolysis inhibitor, U73122 (78±4.05% inhibition) or by a selective Gαs 
protein inhibitor, NF449 (75±0.98% inhibition). Similarly, INT-777 stimulated PI 
hydrolysis was inhibited by U73122 (55±6.96% inhibition) and NF449 (65±5.02% 
inhibition). These results suggest that activation of PI hydrolysis by OA and INT-777 
was mediated via activation of Gαs proteins, probably involving activation of Epac and 
Epac-dependent PLC-ε. In support to this notion, the selective Epac ligand also 
stimulated PI hydrolysis and the extent of stimulation (849±26.77 cpm/mg protein; 
209.5±5.99% increase above basal levels) was similar to INT-777.  Stimulation of PI 
hydrolysis by Epac ligand was inhibited by U73122 (63±7.25% inhibition).  
 
2.3.3.5. Release of Calcium by selective TGR5 ligands 
 To determine whether stimulation of PI hydrolysis cause increase in intracellular 
calcium concentration, we examined the effect of TGR5 ligands on cytosolic Ca2+ 
([Ca2+]I) by calcium imaging using fura-2. Consistent with the activation of PI hydrolysis, 
addition of OA or LCA to MIN6 cells resulted in a rapid increase in cytosolic Ca2+ 
(Figure 19). A similar increase in cytosolic Ca2+ in response to OA was demonstrated in 
islets isolated from mouse and human (Figure 19). These results suggest that TGR5-
mediated increase in intracellular calcium causes the release of insulin from the 
pancreatic human and mouse islets and β cells.   
2.3.3.6. Signaling pathways involved in TGR5-mediated insulin secretion in 
pancreatic β cells 
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 To examine the mechanisms involved in OA-induced insulin secretion, MIN6 
cells were preincubated with inhibitors of Gαs (NF449, 10 µM), PI hydrolysis (U73122, 
10 µM) or with Ca2+ chelator BAPTA-AM (10 µM), and then the insulin secretion in 
response to 50 µM OA was measured. OA caused an increase in insulin secretion in 
both basal (3.7±0.14 fold increase above 3 mM glucose basal levels 29.3±0.3 ng/ml) 
and stimulated (3.6±0.27 fold increase above 25 mM glucose basal levels 49.4±0.1 
ng/ml) condition; increase in insulin secretion was abolished by incubation of cells with 
NF449, U73122 or BAPTA-AM  (Figure 20).  
 In summary, pancreatic human and mouse islets, and pancreatic β cells express 
TGR5 receptors coupled to Gs and stimulation of adenylyl cyclase leading to generation 
of cAMP. Activation of TGR5 by bile acids causes insulin secretion via sequential 
activation Gαs/cAMP, cAMP-dependent exchange factor Epac and Epac-dependent 
PLC-ε. Stimulation of PLC-ε hydrolyzes PIP2 leading to the generation of IP3 and IP3-
dependent Ca2+ release. This rise in the intracellular calcium triggers the release of 
insulin (Figure 21). 
 
 
2.4. Discussion 
     The regulated synthesis and secretion of insulin is one of the center-pieces of the 
body’s strategy to maintain metabolic homeostasis. It is therefore not surprising that 
pancreatic islet β cell function is modulated by neural, endocrine and paracrine factors 
and cell–cell interactions [68,73,78]. A wide variety of ligands thus bind their specific 
receptors on islet cells, which integrates these signals to modulate its synthetic and 
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secretory functions. Bile acids have recently been shown as one of the ligands that 
affect islet function. Specifically, via binding to FXR, bile acids have been shown to 
affect insulin secretion. This study demonstrates that islet β cells also express TGR5 
receptors, which upon activation enhance glucose-mediated insulin secretion. This 
discovery further supports a role for bile acids, the endogenous ligands for TGR5, in the 
regulation of metabolism. 
     Bile acids may impact islet function in both direct and indirect ways.  At the level 
of the intestine, activation of TGR5 by bile acids enhance GLP-1 and GLP-2 release 
[65,109,110]. GLP-1 delays gastric emptying and thus the absorption of glucose, 
thereby flattening the post-prandial glycemic response [85,86]. GLP-1 also directly 
functions as a trophic factor for islet cells and promotes insulin secretion following a 
glucose challenge [67]. The current study demonstrates that bile acids promote 
glucose-mediated insulin secretion via TGR5 expressed on β cells and also confirm 
prior observations that FXR activation can enhance glucose-mediated insulin secretion 
[111]. 
 At a cellular level, TGR5 ligands lithocholic acid, OA and INT-777 all increased 
intracellular Ca2+ and calcium chelation blunted the insulin secretory response indicating 
that the final exocytosis of insulin via TGR5 involved classical Ca2+-dependent 
pathways used by other stimulators of insulin secretion. We further showed that bile 
acid induced TGR5 receptors in the pancreatic β cells is Gαs coupled and activation of 
these receptors leads to stimulation of adenylyl cyclase activity generating cAMP which 
in turn leads to the activation of cAMP-dependent Epac/PLC-ε pathway stimulating 
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insulin secretion. This mechanism was found to be similar to that used by the TGR5 
expressed in the enteroendocrine cells which stimulated GLP1 release [109].   
 Normally, circulating glucose is the key driver of insulin secretion; islet cells 
sense ambient glucose levels along with fatty acids and various amino acids and 
activate proinsulin synthesis and insulin secretory mechanisms in response to the 
metabolic coupling factors [98-103]. The observed enhancement of insulin secretion by 
TGR5 ligands under low and high glucose conditions suggests that the known insulin-
sensitizing effects of bile acids may be partly due to improved insulin secretory 
responses to a glucose load. Interestingly, the simultaneous use of a FXR agonist (INT-
747) and a TGR5 agonist (INT-777) did not lead to an additive response although both 
INT-747 and INT-777 stimulated glucose mediated insulin secretion to a similar degree 
when used alone (data not shown). This suggests a degree of antagonism between the 
intracellular pathways activated by FXR and TGR5 respectively that converge on insulin 
secretion. This however remains to be experimentally elucidated. 
 The concentration of bile acids in circulation fluctuate in fasting and fed state and 
it is known that bile acid levels and form are affected in disease conditions [6,39]. The 
precise effect of bile acids in vivo is likely to be not only a function of its concentration 
but also the nature of the circulating bile acids. For example, it is well known that tauro-
ursodeoxycholic acid is only a weak ligand for TGR5 and FXR whereas 
chenodeoxycholic acid and lithocholic acid are more potent ligands. In chronic liver 
disease, particularly with cholestasis, fasting levels of bile acids are elevated and there 
is a loss of secondary bile acids [112,113]. There is also a decrease in intestinal 
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exposure to bile acids, which is expected to dampen the incretin response to meals. 
The contribution of these findings to the well-known susceptibility of individuals with 
cirrhosis to develop type 2 diabetes now need to be considered in the context of the 
increasing recognition of the effects of bile acids on both insulin secretion and also on 
insulin sensitivity. 
 From a public health point of view, type 2 diabetes is a leading threat to the 
health of human race.  Fasting hyperinsulinemia and eventual β cell exhaustion are 
hallmarks of the insulin resistance syndrome and development of type 2 diabetes [114]. 
It is generally believed that a combination of increased exposure to inflammatory 
cytokines, fatty acids and other products of lipolysis along with increased blood sugar 
drive increased insulin synthesis and secretion in such cases [115]. The potential role of 
bile acids in modulating the insulin secretory response to these factors and as a disease 
modifier in the genesis of type 2 diabetes awaits elucidation. 
 In summary, the current study adds to the growing body of evidence supporting a 
key role of bile acids as a regulator of nutritional and metabolic homeostasis. It activates 
the release of GLP-1, a known stimulator of insulin secretion, in response to a meal in 
the intestine by activation of TGR5 receptors [65,66,109,110]. We now demonstrate that 
TGR5 receptors are present in pancreatic islet β cells and that activation of TGR5 
increases insulin secretion under both low and high ambient glucose levels. 
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Figure 4. Isolation and culture of mouse islets. (A) The mouse was euthanized using 
CO2 and the abdomen was completely opened from the anus to the diaphragm so that 
the mouse upper intraperitoneal cavity was well exposed. The common bile duct was 
clamped off at the duodenum and collagenase P was injected through the common bile 
duct. The inflated pancreas was then removed and subjected to density gradient 
centrifugation and series of washing. (B) The islets initially obtained were found along 
with some acinar tissues which were then removed and (C) the purified islets were 
cultured in RPMI-1640 and incubated at 37°C in 5% CO2. 
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Figure 5. Expression of TGR5 in pancreatic β cell lines. Total RNA isolated from the 
cultured cells (INS1, 823/13 or MIN6) was reverse transcribed and TGR5 mRNA levels 
were measured by qRT-PCR. The results are expressed as fold change or fold 
difference in TGR5 expression levels in reference to INS1 after normalizing with the 
endogenous control, β-actin. TGR5 expression was higher in MIN6 when compared to 
823/13 or INS1 cells. Values are expressed as mean ± SEM of 4 experiments. *p<0.05 
vs. INS1.  
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Figure 6. Expression of TGR5 in human and mouse pancreatic islets. A and B: 
mRNA expression- Total RNA isolated from human and mouse pancreatic islets and 
MIN6 cells was reverse transcribed and expression of TGR5 mRNA was examined by 
RT-PCR using specific primers. The results show representative PCR products (human 
TGR5- 277 bp or mouse TGR5- 104 bp) analyzed on 2% agarose gel containing 
ethidium bromide using Gel DocTM EZ imager. C: Protein expression- Cell lysates 
containing equal amounts of total proteins from MIN6 cells and mouse islets were 
separated on SDS-PAGE and the expression of TGR5 (35 kDa) was analyzed using 
TGR5 selective antibody. 
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Figure 7. Stimulation of insulin secretion by oleanolic acid (OA) in MIN6 cells. 
MIN6 cells were plated at a density of 5 x 105 cells in 24-well plates and cultured with 
DMEM until confluent. The cells were washed and incubated in HBSS buffer containing 
3 mM glucose for 2 h at 370C. The cells were then treated with different concentrations 
of OA (10, 30 or 50 µM) in the presence of 3 mM glucose or 25 mM glucose for 30 min. 
The supernatants were collected and insulin secretion was measured by ELISA. OA 
caused an increase in the insulin secretion in a dose dependent manner both at basal 
and stimulated glucose conditions. Values are expressed as mean ± SEM of 4 
experiments. ##p<0.001 or #p<0.05 vs. 3 mM glucose basal;  **p<0.001 or *p<0.05  vs. 
25 mM glucose basal. 
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Figure 8. Stimulation of insulin secretion by lithocholic acid (LCA) in MIN6 cells. 
MIN6 cells were plated at a density of 5 x 105 cells in 24-well plates and cultured with 
DMEM until confluent. The cells were washed and incubated in HBSS buffer containing 
3 mM glucose for 2 h at 370C. The cells were then treated with physiological 
concentration of LCA (10 µM) in the presence of 3 mM glucose or 25 mM glucose for 30 
min. The supernatants were collected and insulin secretion was measured by ELISA. 
The natural bile acid, LCA increased insulin secretion both at basal and stimulated 
glucose conditions. Values are expressed as mean ± SEM of 4 experiments. ##p<0.001 
or #p<0.05 vs. 3 mM glucose basal;  **p<0.001 or *p<0.05  vs. 25 mM glucose basal. 
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Figure 9. Stimulation of insulin secretion by TGR5 ligands in mouse pancreatic 
islets. Mouse islets (20-25 islets/condition) were washed and incubated in HBSS buffer 
containing 3 mM glucose for 2 h at 370C. The islets were then treated with OA (25 µM) 
or INT-777 (25 µM) or LCA (25 µM) in the presence of 3 mM glucose or 25 mM glucose 
for 30 min. The supernatants were collected and insulin secretion was measured by 
ELISA. Oleanolic acid, a selective TGR5 ligand; INT-777, a specific TGR5 ligand and 
lithocholic acid, a natural bile acid increased insulin secretion in mouse islets. Values 
are expressed as mean ± SEM of 3 experiments. ##p<0.001 or #p<0.05  vs. 3 mM 
glucose basal;  **p<0.001 or *p<0.05  vs. 25 mM glucose basal. 
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Figure 10. Stimulation of insulin secretion by TGR5 ligands in human pancreatic 
islets. Human islets (15-20 islets/condition) were washed and incubated in HBSS buffer 
containing 3 mM glucose for 2 h at 370C. The islets were then treated with OA (25 µM) 
or INT-777 (25 µM) or LCA (25 µM) in the presence of 3 mM glucose or 25 mM glucose 
for 30 min. The supernatants were collected and insulin secretion was measured by 
ELISA. Oleanolic acid, INT-777 and lithocholic acid caused an increase in insulin 
secretion in human islets both at basal and stimulated glucose conditions. Values are 
expressed as mean ± SEM of 3 experiments. ##p<0.001 or #p<0.05  vs. 3 mM glucose 
basal;  **p<0.001 or *p<0.05  vs. 25 mM glucose basal. 
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Figure 11. Selective activation of Gαs by OA in MIN6 cells. Membranes from MIN6 
cells were treated with OA (10 µM) in the presence of [35S]GTPγS for 30 min at 370C. 
Aliquots were added to the wells precoated with specific antibodies to Gαs, Gαq, Gαi1, 
Gαi2 or Gαi3 and incubated for 2 h. The amount of bound radioactivity was measured by 
liquid scintillation and the results are expressed as counts per minute per milligram of 
protein.	  Incubation of MIN6 cell membranes with OA caused a significant increase in the 
binding of [35S]GTPγS selectively to Gαs but not Gαq, Gαi1, Gαi2 or Gαi3. Values are 
expressed as mean ± SEM of 4 experiments. **p<0.001 vs. basal. 
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Figure 12. Selective activation of Gαs by INT-777 in MIN6 cells. Membranes from 
MIN6 cells were treated with INT-777 (25 µM) in the presence of [35S]GTPγS for 30 min 
at 370C. Aliquots were added to the wells precoated with specific antibodies to Gαs, 
Gαq, Gαi1, Gαi2 or Gαi3 and incubated for 2 h. The amount of bound radioactivity was 
measured by liquid scintillation and the results are expressed as counts per minute per 
milligram of protein. Selective activation of Gαs was demonstrated in response to INT-
777 in MIN6 cells. Values are expressed as mean ± SEM of 4 experiments. **p<0.001 
vs. basal. 
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Figure 13. Activation of adenylyl cyclase by TGR5 ligands in MIN6 cells. Adenylyl 
cyclase activity was measured as cAMP formation in MIN6 cells. The cells were treated 
with TGR5 ligands (OA or INT-777, 25 µM) for 5 min in the presence of 100 µM 
isobutylmethylxanthine (IBMX) and cAMP formation was measured by 
radioimmunoassay. Results are computed from a standard curve using Prism
@ 
and 
expressed as percent increase in cAMP levels above basal levels (0.32 pmoles/ml). The 
TGR5 ligands, OA and INT-777 caused a significant (p<0.01) increase in cAMP 
formation. Values are expressed as mean ± SEM of 3 experiments.  
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Figure 14. Effect of PKA inhibitor on OA-induced insulin secretion. MIN6 cells 
were treated with OA (50 µM) in the presence or absence of PKA inhibitor 
(myristoylated PKI, 1 µM). After 30 min, the supernatant was collected and insulin 
secretion was measured by ELISA. The TGR5 ligand, OA stimulated insulin secretion 
and the selective PKA inhibitor, Myr PKI had no significant inhibition on OA-induced 
insulin secretion. Values are expressed as mean ± SEM of 3 experiments. ##p<0.001 vs. 
3 mM glucose basal; **p<0.001 vs. 25 mM glucose basal. 
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Figure 15. Schematic representation of cAMP-mediated signaling pathway.  
Activation of a Gαs coupled receptors generates cAMP.  The effect of cAMP is mediated 
by two different mechanisms: the classical cAMP-dependent protein kinase (PKA) 
pathway and non-canonical cAMP-dependent PKA-independent pathway involving 
activation of exchange factor Epac and stimulation of phosphoinositide-specific 
phospholipase C-ε (PLC-ε) leading to generation of IP3 and IP3-dependent Ca2+ release.  
This rise in the intracellular calcium triggers the release of insulin in pancreatic β cells.  
 
	  	   52	  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Stimulation of insulin secretion by the selective Epac ligand. MIN6 cells 
were treated with the Epac ligand, 8-pCPT-2'-O-Me-cAMP (10 µM). After 30 min, the 
supernatant was collected and insulin secretion was measured by ELISA. The Epac 
ligand stimulated insulin secretion at both basal and stimulated glucose conditions. 
Values are expressed as mean ± SEM of 3 experiments. ##p<0.001 vs. 3 mM glucose 
basal; **p<0.001 vs. 25 mM glucose basal. 
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Figure 17. Expression of Epac1, Epac2 or PLC-ε in MIN6 cells, mouse and human 
islets. Total RNA was isolated from cultured MIN6 cells, mouse and human islets and 
reverse transcribed using 1 µg of total RNA. The cDNA was amplified using specific 
primers and examined for the expression of Epac1 (mouse- 159 bp, human- 130 bp), 
Epac2 (mouse- 195 bp, human- 203 bp) or PLC-ε (mouse- 606 bp, human- 82 bp) by 
RT-PCR. The results show representative PCR products analyzed on 2% agarose gel 
containing ethidium bromide using Gel DocTM EZ imager. Gapdh or β-actin was used as 
a loading control. 
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Figure 18. Activation of PI hydrolysis by TGR5 or Epac ligand in MIN6 cells.  
MIN6 cells were labeled with myo-[3H] inositol for 24 h and then treated with OA (10 
µM), INT-777 (25 µM) or Epac ligand (8-pCPT-2'-O-Me-cAMP, 10 µM) with or without 
the selective Gαs inhibitor (NF449, 10 µM) or PI hydrolysis inhibitor (U73122, 10 µM). PI 
hydrolysis was measured by ion exchange chromatography and the results are 
expressed as percent increase above basal levels. OA or INT-777 stimulated PI 
hydrolysis and the stimulation was blocked with the pretreatment of cells with the 
inhibitors of Gαs (NF449) and phospholipase C (U73122). Stimulation of PI hydrolysis 
by Epac ligand was inhibited by U73122.  Values are expressed as mean ± SEM of 3 
experiments. **p<0.001 significant inhibition in PI hydrolysis compared to OA, INT-777 
or Epac ligand.  
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Figure 19. Release of intracellular calcium by TGR5 ligands. MIN6 cells, mouse 
islets and human islets were loaded with 5 µM fura-2AM in HBSS buffer for 2 h at room 
temperature. Clusters of cells were selected for imaging and visualization. The cells 
were alternatively excited at 340 nm and 380 nm and the change in cytosolic calcium in 
response to OA or LCA were measured by determining the ratio of the fluorescence of 
fura-2 at 340 and 380 nm excitation. Addition of OA or LCA to MIN6 cells resulted in a 
rapid increase in cytosolic Ca2+. A similar increase in cytosolic Ca2+ in response to OA 
was observed in both mouse and human islets. Representative traces with each ligand 
are shown.   
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Figure 20. Effect of Gαs and PI hydrolysis inhibitor and calcium chelator on OA-
induced insulin secretion. MIN6 cells were treated with OA (50 µM) in the presence or 
absence of selective Gαs inhibitor (NF449, 10 µM), PI hydrolysis inhibitor (U73122, 10 
µM) or calcium chelator (BAPTA-AM, 10 µM). After 30 min, the supernatant was 
collected and insulin secretion was measured by ELISA. Basal and glucose-stimulated 
insulin secretion was significantly augmented by OA.  The effect of OA was blocked by 
NF449, U73122 or BAPTA-AM.   Values are expressed as mean ± SEM of 3 
experiments. ##p<0.001 vs. 3 mM glucose basal; **p<0.001 vs. 25 mM glucose basal. 
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Figure 21. Schematic representation of the signaling pathway coupled to TGR5 
receptors to mediate insulin secretion from pancreatic β cells. TGR5 receptors 
expressed in the pancreatic β cells are Gαs coupled and activation of these receptors by 
bile acids leads to the stimulation of PI hydrolysis via a cAMP-dependent mechanism 
involving Epac/PLC-ε/Ca2+ pathway and stimulation of insulin secretion. Inhibitors of Gs 
activation with NF449, PI hydrolysis with U73112 or chelation of intracellular Ca2+ with 
BAPTA-AM blocked the effect of TGR5 activation on insulin release. 
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3.1. Introduction 
  We have previously shown that activation of TGR5, a novel G-protein coupled 
receptor by bile acids induce insulin secretion in pancreatic β cells [116]. Pancreatic 
islets, in addition to β cells also contain glucagon secreting α cells and somatostatin 
secreting δ cells along with other cell types [68,74]. The regulation of blood glucose 
homeostasis is maintained by the opposing actions of the dual hormonal system, which 
constitute insulin and glucagon [117]. Post prandial hyperglycemia (fed state) stimulates 
insulin secretion from pancreatic β cells, whereas hypoglycemia (fasted state) 
stimulates glucagon secretion from the pancreatic α cells [118].  
 Glucagon increases blood glucose levels, an effect that is opposite to that of 
insulin and is therefore known as insulin antagonist [119]. Glucagon is a peptide 
hormone consisting of 29 amino acids and is generated from the cleavage of 
proglucagon by the enzyme prohormone convertase 2 (PC2) in the pancreatic α cells 
[68,85]. Glucagon secretion is not only regulated by glucose concentration but is 
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complex and is also regulated by nutrients such as amino acids and fatty acids and by 
neural, hormonal and cellular interactions [68,120]. Under physiological state, in 
response to hypoglycemia or low glucose conditions, glucagon is secreted into the 
blood stream from the pancreatic α cells [118]. The secreted glucagon acts 
predominantly on the liver. Glucagon upon binding to its receptor (G protein coupled 
receptor) trigger downstream signaling pathway mostly via Gαs [119]. Glucagon 
signaling regulates the expression or activity of the enzymes involved in glucose 
metabolism [121]. The liver is a major site of glucagon’s physiological actions and it is 
exposed to 2-3 times higher concentration of glucagon than other organs.  In the liver 
glucagon promotes gluconeogenesis and glycogenolysis, and simultaneously inhibit 
glycolysis and glycogenesis to restore glucose homeostasis [118]. In the adipose tissue, 
glucagon facilitates lipolysis [117]. In addition, glucagon also stimulates insulin secretion 
from the pancreatic β cells and indirectly impact hepatic glucose output [118]. In 
summary, glucagon plays a pivotal role in maintaining fuel homeostasis along with 
insulin. 
 Hypoglycemic conditions trigger glucagon release from α cells by 3 different 
mechanisms: i) direct stimulatory effect of α islet cell by hypoglycemia; ii) suppression 
inhibitory effect of islet β cell; and iii) autonomic stimulation of α islet cell. Under 
hypoglycemic conditions, glucose is transported via GLUT1 and facilitates moderate 
activity of KATP channels in the pancreatic α cells. This event is followed by sequential 
activation of T type Ca2+ channels and voltage dependent Na+ channels which further 
potentiates the opening of L type Ca2+ channels. The resultant firing of large amplitude 
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action potential leads to influx of Ca2+ and exocytosis of glucagon [120]. Whereas under 
hyperglycemic conditions, closure of KATP channels decreases α cell action potential and 
subsequent activation of voltage gated channels leading to inhibition of glucagon 
secretion [119]. This is opposite to the pattern observed in β cells in response to 
glucose and studies have shown that pancreatic β cells differ from α cells in being 
electrically active only at high glucose conditions [120].  
 Pancreatic α cells also express several G protein coupled receptors such as 
somatostatin receptors, GLP-1 receptors, fatty acid receptors, adrenergic receptors etc 
but unlike the overwhelming information available on GPCRs expressed on β cells, 
alpha cell GPCRs are not well studied [81,82]. In the present study upon examining the 
expression of TGR5 in αTC1-6 cells, we postulated that activation of TGR5 at low 
glucose conditions stimulates glucagon secretion from pancreatic α cells.    
 
3.2. Materials and Methods 
3.2.1. Materials 
 Oleanolic acid (OA) and lithocholic acid (LCA) were obtained from Sigma-Aldrich 
(St Louis, MO) and INT-777 (S-EMCA: 6α-Ethyl-23(S)-methylcholic Acid) was a 
generous gift from Intercept Pharmaceuticals. Antibody to TGR5 was purchased from 
Abcam (Cambridge, MA); Glucagon ELISA kit was obtained from R & D systems 
(Minneapolis, MN). Collagenase P was obtained from Roche Diagnostics (Indianapolis, 
IN); HEPES and RPMI were obtained from Invitrogen (Eugene, OR); western blotting 
and chromatography materials were obtained from Bio-Rad Laboratories (Hercules, 
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CA). RNeasy Plus universal Mini kit was obtained from Qiagen (Venlo, Netherland); 
PCR reagents were obtained from Applied Biosystems (Foster city, CA); Dulbecco’s 
Modified Eagle Medium (DMEM), 2-mercaptoethanol, Histopaque (10771 and 11191) 
and all other reagents were obtained from Sigma (St Louis, MO).  
 Wild type C57BL/6J mice were purchased from Jackson laboratories (Ban 
Harbor, ME) and euthanized with CO2. The animals were housed in the animal facility 
administered by the Division of Animal Resources, Virginia Commonwealth University. 
All procedures were conducted in accordance with the institutional Animal Care and 
Use Committee of the Virginia Commonwealth University.  
3.2.2. Cell culture 
 The insulin secreting pancreatic beta (β) cell line, MIN6 cells were cultured in 
DMEM containing L-glutamine, sodium carbonate, 2.5 mM 2-mercaptoethanol; 
glucagon secreting pancreatic alpha (α) cell line, αTC1-6 cells (obtained from ATCC) 
were cultured in DMEM containing HEPES, non-essential amino acids (NEAA), bovine 
serum albumin (BSA), sodium carbonate and somatostatin secreting pancreatic delta 
(δ) cell line, TGP52 cells (obtained from ATCC) were cultured in DMEM: F12 medium. 
All the media were supplemented with 10% fetal bovine serum and 100U/ml pencillin-
streptomycin and the cells were incubated at 37°C in 5% CO2. 
3.2.3. Isolation and maintenance of mouse islets 
 Pancreatic islets from mice were isolated by sequential enzymatic digestion of 
pancreas, filtration and centrifugation as described previously [Chapter 2]. The isolated 
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mouse islets were cultured in RPMI-1640 medium supplemented with 10% FBS and 
100U/ml pencillin-streptomycin and incubated at 37°C in 5% CO2.  
 
 
3.2.4. RNA Isolation and RT-PCR analysis 
 Total RNA was isolated from cells (αTC1-6, MIN6 and TGP52) and mouse islets 
using RNeasy Plus Universal Mini Kit (Qiagen) following manufacturer’s instructions. 
The purified RNA was reverse transcribed to single stranded cDNA and conventional 
PCR was carried out as described previously [Chapter 2]. The amplified PCR products 
were analyzed on 2% agarose gel containing ethidium bromide using Gel DocTM EZ 
imager. 
3.2.5. Western blot analysis 
 Equivalent amounts of protein were resolved by SDS-PAGE and transferred onto 
a nitrocellulose membrane.  Blots were blocked in 5% nonfat dry milk for 1 h followed by 
immunobloting with anti-TGR5 antibody and anti-rabbit IgG horseradish peroxidase 
secondary antibody as described previously [chapter 2]. Blots were visualized using 
advanced ECL western blotting detection reagents. 
3.2.6. Measurement of Glucagon secretion 
 αTC1-6 cells were plated at a density of 5 x 105 cells in 24-well plates with DMEM 
medium and cultured until confluent. The cells were washed and incubated in HBSS 
(114 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.16 mM MgSO4, 20 mM HEPES, 2.5 
mM CaCl2, 25.5 mM NaHCO3, pH 7.2, 0.1% BSA) containing 16.7 mM glucose for 2 h 
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at 370C.  Cells were then treated for 1 hour in HBSS containing 3 mM glucose with or 
without OA, INT-777 or LCA. The supernatants were collected and assayed for 
glucagon using ELISA kit. For glucagon secretion from mouse islets (25-30 
islets/condition), the islets were incubated at 370C for 2 h in HBSS with 16.7 mM 
glucose. The same procedure as described above was followed. 
3.2.7. Statistical Analysis 
 Results were calculated as means ± SEM and the experiments were performed 
at least three times. The experiments were performed on islets isolated from different 
animals. Statistical significance was analyzed using Student’s t-test for paired and 
unpaired values. GraphPad Prism software was used for all statistical analyses and p 
values < 0.05 were considered significant. 
 
3.3. Results 
3.3.1. Expression of TGR5 in pancreatic α, β and δ cell lines and mouse islets 
 To study the role of TGR5 in the regulation of glucagon secretion from pancreatic 
alpha (α) cells, we examined the expression of TGR5 receptors by RT-PCR and 
western blot. RT-PCR analysis using RNA isolated from αTC1-6 cells, a PCR product of 
the expected size (104 bp) was obtained with TGR5 specific primers (Figure 22A).  
 We have previously shown that TGR5 is expressed in pancreatic β cell line, 
MIN6 cells and mouse and human islets [116]. Since islets represent a mixture of cells 
consisting predominantly β, α and δ cells, we also examined whether TGR5 is 
expressed in the pancreatic α cells (αTC1-6) and δ cells (TGP52). Western blot analysis 
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using specific antibody to TGR5 demonstrated the presence of TGR5 protein (35 kDa) 
in the lysates derived from αTC1-6, MIN6, TGP52 cells and mouse islets (Figure 22B). 
3.3.2. Stimulation of glucagon secretion by TGR5 ligands in αTC1-6 cells 
 To address the functional significance of TGR5 receptors in α cells, the effect of 
TGR5 ligands (OA, INT-777 or LCA) on glucagon secretion was examined.  Basal levels 
of glucagon released under low (3 mM) conditions were 4665±5 pg/ml. Treatment of 
αTC1-6 cells for 1 hour at low glucose conditions with OA, INT-777 or LCA significantly 
stimulated glucagon secretion above basal levels (1.6±0.01 fold increase with INT-777, 
1.7±0.02 fold increase with OA and 1.6±0.11 fold increase with LCA) (Figure 23). 
 The stimulatory effect of INT-777 on glucagon secretion is concentration-
dependent (10 µM- 1.2±0.04, 25 µM- 1.45±0.07, 50 µM- 1.51±0.07 fold increase above 
3 mM glucose basal levels, 4283±13 pg/ml). Similarly, the effect of LCA was also 
concentration-dependent (10 µM- 1.09±0.03, 25 µM- 1.4±0.02, 50 µM- 1.44±0.07 fold 
increase above 3 mM glucose basal levels) (Figures 24A and 24B). 
 3.3.3. Stimulation of glucagon secretion by TGR5 ligands in mouse islets 
  We also examined the effect of TGR5 ligands on glucagon secretion from mouse 
pancreatic islets.  Basal levels of glucagon release from islets under low (3 mM) 
conditions were 37.8± 1.2 pg/islet. Treatment of islets with 25 µM INT-777 or OA 
significantly increased glucagon secretion (INT-777, 1.7±0.03 fold increase and OA, 
1.5±0.08 fold increase above basal levels).  Similarly, treatment of islets with 25 µM 
natural bile acid, LCA significantly increased glucagon secretion (1.4±0.01 fold increase 
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above basal level) (Figure 25). The extent of increase in glucose secretion with all three 
TGR5 ligands was similar.   
 
3.4. Discussion 
 Secretion of glucagon, the counter regulatory hormone of insulin, is stimulated in 
response to hypoglycemia and plays a vital role in restoring normoglycemia [117]. 
Previously it has been shown that low glucose concentrations, amino acids (especially 
alanine or arginine), cholecystokinin, epinephrine or acetylcholine stimulate glucagon 
secretion from pancreatic α cells [119,120]. In the present study, it is demonstrated that 
pancreatic α cells also express TGR5 receptors, which upon activation with 
pharmacological ligands (OA or INT-777) and natural ligand (LCA) stimulate glucagon 
secretion providing evidence for an additional role of bile acids in glucose homeostasis.  
 Bile acids may also regulate glucagon secretion via release of GLP-1 from 
enteroendocrine cells. GLP-1 in addition to stimulating insulin secretion from the 
pancreatic β cells also suppresses glucagon secretion from α cells [67,88]. The current 
study demonstrates that activation of TGR5 by bile acids also promotes glucagon 
secretion under low conditions. We have demonstrated the glucagon secretion in 
response to TGR5 activation in both mouse pancreatic islets and in αTC1-6 cells, a 
mouse pancreatic α cell line. Hypoglycemic conditions trigger glucagon release from α 
cells both by direct and indirect mechanisms involving paracrine regulation via β and δ 
cells secretion. αTC1-6 cells are homogenous cell population that do not express insulin 
or somatostatin and is therefore considered a good model to examine glucagon 
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secretion or alpha cell gene expression [122]. The extent of stimulation of glucagon 
secretion appears to be similar in both αTC1-6 cells and mouse islets. These results 
suggest that, at least under low glucose conditions, secretion is mostly under direct 
effect of hypoglycemia.    
 Previous studies have shown that αTC1-6 cells secrete glucagon in response to 
nutrients and activation of Gs-coupled receptors [119]. We found that activation of TGR5 
by INT-777 or LCA stimulated glucagon secretion in a dose dependent manner under 
low (3 mM) glucose conditions in αTC1-6 cells. Our data is similar to the previous 
studies, which describes the stimulatory effect of amino acids or free fatty acids to 
promote glucagon secretion under low glucose conditions [123,124]. Similarly we have 
shown that the stimulatory effect of low glucose is further amplified by the TGR5 ligands 
to release glucagon in mouse islets.  
 The insulin producing β cells and glucagon producing α cells are featured with 
unique set of ion channels and the two cell types are well coordinated within the 
pancreatic islet to fine tune the secretion of hormone and thus regulate glucose 
homeostasis [118,120]. Glucagon secretion is inhibited by hyperglycemia, in contrast to 
increase in insulin secretion. The threshold for suppression of glucagon release is lower 
than β cells suggesting that α cells are more sensitive to glucose than β cells [119]. In 
contrast to opposing effect of glucose on glucagon and insulin secretion, amino acids 
stimulate release of both glucagon and insulin [120]. Free fatty acids also affect 
glucagon secretion. Saturated fatty acids are more effective in stimulating glucagon 
secretion than unsaturated fatty acids [125]. The mechanisms involved in TGR5-
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mediated glucagon secretion from pancreatic α cells remains to be elucidated. It is 
possible that TGR5 utilizes the same Gs/cAMP/Epac/PLC-ε/Ca2+ pathway to mediate 
glucagon secretion as this pathway was shown to be involved in insulin secretion from 
islet β cells and GLP-1 secretion from enteroendocrine cells in response to activation of 
TGR5 [109]. The physiological significance of TGR5 in α cells is also unclear. Levels of 
systemic bile acids in hypoglycemic (fast state) conditions are 3 times lower than the 
post prandial state and increased glucose levels under post prandial state suppress 
glucagon release from α cells. Previous studies have shown that other neurohumoral 
agents (e.g., acetylcholine, sphingosine-1-phosphate) also interact with TGR5 receptors 
in different cell types. The significance of the possibility of TGR5 activation by ligands 
other than bile acids under hypoglycemic conditions remains to be determined.   
 In conclusion, the current study provide evidence to the regulation of pancreatic α 
cell function by bile acids via activation of TGR5 in addition to the regulation of insulin 
secretion from β cells [116]. With a better understanding of the intra islet regulation of 
insulin secretion, new therapeutic strategies for the treatment of diabetes can be 
targeted not only on the approaches that suppress liver glucose production but also on 
enhancing intraislet glucagon action. Unlike antidiabetic drugs like sulphonylurea 
derivatives, which pose the risk of hypoglycemia [87,91], the use of TGR5 ligands may 
serve a better therapeutic approach in the management of T2D and awaits further 
elucidation.
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Figure 22. Expression of TGR5 in pancreatic α, β and δ cell lines and mouse 
islets. A: mRNA expression- Total RNA isolated from αTC1-6 (α cell line), MIN6 (β cell 
line), TGP52 (δ cell line) cells and mouse islets was reverse transcribed and expression 
of TGR5 mRNA was examined by RT-PCR using specific primers. The results show 
representative PCR products (TGR5- 104 bp, Gapdh- 122 bp) analyzed on 2% agarose 
gel containing ethidium bromide using Gel DocTM EZ imager. B: Protein expression- 
Cell lysates containing equal amounts of total proteins from αTC1-6, MIN6, and TGP52 
cells and mouse islets were separated on SDS-PAGE and the expression of TGR5 was 
analyzed using TGR5 selective antibody. A band corresponding to 35 kDa was detected 
by chemilumiscence. The membrane was reprobed for β-actin (42 kDa), an endogenous 
loading control. 
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Figure 23. Stimulation of glucagon secretion by TGR5 ligands in αTC1-6 cells. 
αTC1-6 cells were plated at a density of 5 x 105 cells in 24-well plates and cultured with 
DMEM until confluent. The cells were washed and incubated in HBSS buffer containing 
16.7 mM glucose for 2 h at 370C. Cells were then treated for 1 hour with TGR5 ligands 
(OA, INT-777 or LCA- 25 µM) in HBSS containing 3 mM glucose. The supernatants 
were collected and glucagon secretion was measured by ELISA. The TGR5 ligands 
increased glucagon secretion in αTC1-6 cells. Values are expressed as mean ± SEM of 
4 experiments. **p<0.001 or *p<0.05  vs. 3 mM glucose basal.  
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Figure 24. Stimulation of glucagon secretion by INT-777 or LCA in αTC1-6 cells. 
αTC1-6 cells were plated at a density of 5 x 105 cells in 24-well plates and cultured with 
DMEM until confluent. The cells were washed and incubated in HBSS buffer containing 
16.7 mM glucose for 2 h at 370C. Cells were then treated for 1 hour with different 
concentrations of INT-777 (10, 25 or 50 µM) or LCA (10, 25 or 50 µM) in HBSS 
containing 3 mM glucose. The supernatants were collected and glucagon secretion was 
measured by ELISA. INT-777 (A) or LCA  (B) caused an increase in the glucagon 
secretion in a dose-dependent manner. Values are expressed as mean ± SEM of 4 
experiments. **p<0.001 or *p<0.05  vs. 3 mM glucose basal.  
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Figure 25. Stimulation of glucagon secretion by TGR5 ligands in mouse 
pancreatic islets. Mouse islets were washed and incubated in HBSS buffer containing 
16.7 mM glucose for 2 h at 370C. The islets  (25-30 islets/condition) were then treated 
with INT-777 (25 µM) or OA (25 µM) or LCA (25 µM) in the presence of 3 mM glucose 
for 1 hour. The supernatants were collected and glucagon secretion was measured by 
ELISA. INT-777 (specific TGR5 ligand), oleanolic acid (selective TGR5 ligand) and 
lithocholic acid (natural bile acid) significantly increased glucagon secretion in mouse 
islets. Values are expressed as mean ± SEM of 3 experiments. **p<0.001 vs. 3 mM 
glucose basal. 	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CHAPTER	  4	  
REGULATION	  OF	  HYPERGLYCEMIA-­‐INDUCED	  PC1	  EXPRESSION	  AND	  	  
GLP-­‐1	  SECRETION	  IN	  PANCREATIC	  α	  CELLS	  BY	  TGR5	  
	  
	  
4.1. Introduction 
 Bile acids via activation of TGR5 regulate glucose homeostasis by improving 
postprandial glycemic levels and insulin sensitivity [38,40,63]. Bile acids that are 
released in response to a meal stimulate GLP-1 secretion from the intestinal 
enteroendocrine cells via activation of TGR5 receptors [65,109,110]. GLP-1 is an 
incretin hormone that stimulates insulin secretion from the pancreatic β cells in a 
glucose dependent manner [67,88]. In addition, GLP-1 exerts a variety of physiological 
effects and plays an important role in integrating nutrient and energy metabolism 
[86,87].  
 GLP-1 is a 30 amino acid peptide hormone that is processed from proglucagon 
by the enzyme prohormone convertase 1 (PC1) in the enteroendocrine L cells [85,89]. 
GLP-1 secretion is highly regulated by nutrients such as fats, carbohydrates and 
proteins as well as via neural signals, endocrine and paracrine factors [83-85]. The 
fasting circulatory levels of GLP-1 are 5-15 pM and increases up to 20-30 pM after 
ingestion of meal [88]. Following its secretion into the blood, GLP-1 is rapidly degraded 
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by the enzyme dipeptidyl peptidase- IV (DPP-IV), and the half life of GLP-1 is less than 
5 minutes [89,91].  
 GLP-1 exerts its action via binding to its receptor which is a seven 
transmembrane G protein coupled receptor expressed on pancreatic islets as well as in 
other tissues including brain, gastrointestinal tract, lung and kidneys [85]. In pancreatic 
islet, GLP-1 stimulates insulin secretion from the β cells in a glucose dependent manner 
[87]. GLP-1 also increases insulin synthesis and promotes β cell proliferation and 
inhibits glucagon secretion from α cells [67,86]. In addition, GLP-1 inhibits gastric 
emptying and food intake and improves insulin sensitivity [85,86]. 
 We have recently shown that bile acids activate TGR5 in pancreatic β cells to 
stimulate insulin secretion in [116]. Insulin secretion is a highly dynamic process and in 
addition to nutrients and neural inputs it is also regulated by hormonal factors such as 
glucagon secreted from the pancreatic α cells and glucagon-like peptide 1 (GLP-1) by 
the intestinal L cells [68,91,95]. Both glucagon and GLP-1 are processed from the same 
precursor, proglucagon in a cell type specific manner. In the pancreatic α cells, 
proglucagon undergoes alternative splicing (post translational modification) by the 
enzyme prohormone convertase 2 (PC2) to yield glucagon whereas proglucagon is 
processed by PC1 to GLP-1 in the enteroendocrine L cells [126,127]. This tissue 
specific processing is due to differential expression of the enzymes PC1 and PC2 [126-
128].  
  We have also shown that TGR5 receptors are expressed on pancreatic α cells 
and activation of these receptors by bile acids at low glucose conditions stimulates 
	  	   74 
glucagon secretion from αTC1-6 cells and mouse islets (Chapter 2). Previous studies 
have shown that under hyperglycemic conditions, there is activation of PC1 in the 
pancreatic α cells leading to GLP-1 production and this was evident in different mouse 
models of diabetes such as STZ-induced diabetic mice, prediabetic NOD mice, db/db 
mice and ob/ob mice [129,130]. These studies suggested that hyperglycemia causes a 
switch in the processing of proglucagon by up regulating PC1 expression leading to 
GLP-1 secretion from the pancreatic α cells [131-133]. Recent studies have shown that 
circulating bile acid concentration are higher in obese patients with type 2 diabetes 
when compared to lean healthy individuals and increased systemic bile acid 
concentrations are associated with the pathophysiology of obesity and type 2 diabetes 
[134,135]. We therefore postulated that under hyperglycemia, activation of TGR5 by bile 
acids in the pancreatic α cells could further upregulate PC1 expression with subsequent 
GLP-1 production and thereby also regulate insulin secretion.   
 
4.2. Materials and Methods 
4.2.1. Materials 
      Oleanolic acid (OA) and lithocholic acid (LCA) were obtained from Sigma-Aldrich 
(St Louis, MO) and INT-777 (S-EMCA: 6α-Ethyl-23(S)-methylcholic Acid) was a 
generous gift from Intercept Pharmaceuticals. PC1 antibody and PC1 plasmid was a 
generous gift from Dr. Lakshmi Devi (Icahn School of Medicine, Mount Sinai, NY)  and 
Dr. Theodore Friedman (Charles R. Drew University of Medicine and Science, Los 
Angeles, CA) respectively. NF449 was obtained from Santa Cruz Biotechnology Inc. 
(Santa Cruz, CA); antibodies to PC2, p-CREB and CREB were obtained from Cell 
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Signaling Technology (Danvers, MA); ultrasensitive human insulin ELISA kit was 
purchased from Mercodia (Uppsala, Sweden); High sensitivity GLP-1 ELISA kit was 
obtained from Millipore (Billerica, MA). Collagenase P was obtained from Roche 
Diagnostics (Indianapolis, IN); HEPES, lipofectamine 2000 and RPMI were obtained 
from Invitrogen (Eugene, OR); U73122, and Myristolyated PKI were obtained from 
Calbiochem (La Jolla, CA); western blotting and chromatography materials were 
obtained from Bio-Rad Laboratories (Hercules, CA). RNeasy Plus universal Mini kit and 
Taq PCR core kit were obtained from Qiagen (Venlo, Netherland); PCR reagents were 
obtained from Applied Biosystems (Foster city, CA); ultrasensitive human insulin ELISA 
kit was purchased from Mercodia (Uppsala, Sweden); BrightGlo lucifearase assay kit 
and pGL2 basic vector were obtained from Promega (Madison, WI). Dulbecco’s 
Modified Eagle Medium (DMEM), 2-mercaptoethanol, 8-pCPT-2'-O-Me-cAMP, BAPTA-
AM, Exendin (9-39), Histopaque (10771 and 11191) and all other reagents were 
obtained from Sigma (St Louis, MO).  
 Wild type C57BL/6J mice, db/db mice (homozygous for leptin receptor) and 
control mice (C57BLKS/J) were purchased from Jackson laboratories (Ban Harbor, ME) 
and euthanized with CO2. The animals were housed in the animal facility administered 
by the Division of Animal Resources, Virginia Commonwealth University. All procedures 
were conducted in accordance with the institutional Animal Care and Use Committee of 
the Virginia Commonwealth University.  
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4.2.2. Cell culture 
 αTC1-6, MIN6 and TGP52 cells were cultured in their respective media as 
described previously [Chapter 3]. The enteroendocrine cells, STC-1 (obtained from 
ATCC) were cultured in DMEM containing L-glutamine, sodium pyruvate (Figure 26). 
All the media were supplemented with 10% fetal bovine serum and 100U/ml pencillin-
streptomycin and the cells were incubated at 37°C in 5% CO2. 
4.2.3. Isolation and maintenance of mouse islets 
 Pancreatic islets from mice were isolated by sequential enzymatic digestion of 
pancreas, filtration and centrifugation as described previously [Chapter 2]. The isolated 
mouse islets were cultured in RPMI-1640 medium supplemented with 10% FBS and 
100U/ml pencillin-streptomycin and incubated at 37°C in 5% CO2.  
4.2.4. RNA Isolation and RT-PCR analysis 
 Total RNA was isolated from cells (αTC1-6, MIN6 and TGP52) and mouse islets 
using RNeasy Plus Universal Mini Kit (Qiagen) following manufacturer’s instructions. 
The purified RNA was reverse transcribed to single stranded cDNA and conventional 
PCR was carried out as described previously [Chapter 2]. The amplified PCR products 
were analyzed on 2% agarose gel containing ethidium bromide using Gel DocTM EZ 
imager. Real time PCR was carried out using StepOneTM Real-Time PCR system 
(Applied Biosystems) and quantification of gene expression was done using relative 
quantification method as described previously [Chapter 2]. 
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4.2.5. Western blot analysis 
 Equivalent amounts of protein were resolved by SDS-PAGE and transferred onto 
a nitrocellulose membrane.  Blots were blocked in 5% nonfat dry milk for 1 h followed by 
immunobloting with respective primary antibody and anti-rabbit IgG horseradish 
peroxidase secondary antibody as described previously [chapter 2]. Blots were 
visualized using advanced ECL western blotting detection reagents. 
 
4.2.6. Assay for phosphoinoside (PI) hydrolysis  
 αTC1- 6 cells cultured in 25 mM glucose for 6-7 days were labeled with myo-[3H] 
inositol (0.5 µCi/ml) in DMEM medium for 24 h. After 24 h, cells were washed with PBS 
and treated with INT-777, NF449 (a selective Gαs inhibitor), 8-pCPT-2'-O-Me-cAMP (a 
selective Epac ligand), U73122 (PI hydrolysis inhibitor) or ESI-05 (Epac2 inhibitor) for 1 
min. The reaction was terminated, samples were extracted and ion-exchange 
chromatography was carried out as described previously [chapter 2].  
4.2.7. Transfection of PC1 plasmid into αTC1- 6 cells 
 αTC1- 6 cells were plated at a density of 5 x 105 cells in 96-well plates in DMEM 
and cultured until confluent. One day before the transfection, the media was changed to 
antibiotic free medium. The cells were then transiently transfected with 0.2 µg PC1 
plasmid (human PC1 luciferase promoter construct, -971 to -1 bp relative to the 
translation initiation codon inserted in the pGL2-basic vector) using lipofectamine 2000 
for 24 hours. Cells were also transfected with plasmid containing red fluorescence 
(pSIREN-DNR-DsRED) and the transfection efficiency was monitored by the expression 
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of the red fluorescent protein using FITC filters. Control cells were transfected with 
vector (pGL2-basic vector) alone. All transfections were done in quadruplets.  
4.2.8. PC1 promoter activity assay 
 αTC1- 6 cells cultured in 96-well plate was transfected using lipofectamine 2000 
as previously described. After 24 hours of transfection, cells were treated with 5 mM 
glucose or 25 mM glucose with or without INT-777 in the presence of specific inhibitors 
for 24 hours. Luciferase activity was measured in a luminometer using BrightGlo assay 
kit (Promega).  
 
4.2.9. Measurement of GLP-1 secretion 
 αTC1-6 cells were plated at a density of 2 x 105 cells in 24-well plates with DMEM 
containing 5 mM glucose or 25 mM glucose and cultured for 6-7 days. The cells were 
then washed and incubated in DMEM containing 5 mM or 25 mM glucose with or 
without OA, INT-777 or LCA for 24 hours. The supernatants were collected and 
assayed for GLP-1 using ELISA kit.  For GLP-1 secretion from control mouse islets, the 
islets were cultured in RPMI-1640 medium containing 5 mM glucose or 25 mM glucose 
for 6-7 days and then treated with or without OA, INT-777 or LCA for 24 hours. The 
islets isolated from db/db mice were cultured in RPMI-1640 medium with or without OA, 
INT-777 or LCA for 24 hours. The supernatant were collected and assayed for GLP-1 
secretion. 25-30 mouse islets were used in each experimental condition. DPP-4 inhibitor 
was added to prevent GLP-1 degradation at a concentration of 10 µl/ml of the medium.  
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4.2.10. Measurement of Insulin secretion 
     Human islets were cultured under low (5 mM) or high (25 mM) glucose conditions 
for 7 days. The islets were washed and incubated in HBSS (114 mM NaCl, 4.7 mM KCl, 
1.2 mM KH2PO4, 1.16 mM MgSO4, 20 mM HEPES, 2.5 mM CaCl2, 25.5 mM NaHCO3, 
pH 7.2, 0.1% BSA) containing 3 mM glucose for 2 h at 370C. Human islets (30-35 
islets/condition) were then treated for 1 hour in HBSS containing 3 mM (basal) or 25 
mM glucose (stimulated) with INT-777 or exendin (9-39) or both. The supernatants were 
collected and assayed for insulin using ELISA kit.   
 
4.2.11. Statistical Analysis 
 Results were calculated as means ± SEM and the experiments were performed 
at least three times. The experiments were performed on islets isolated from different 
animals. Statistical significance was analyzed using Student’s t-test for paired and 
unpaired values. GraphPad Prism software was used for all statistical analyses and p 
values < 0.05 were considered significant. 
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Table 2. RT-PCR primer sequences. Primers used for the amplification of different 
genes. TGR5- Taketa G-Protein coupled receptor 5, PC1- prohormone convertase 1, 
PC2- prohormone convertase 2, Epac- exchange proteins activated by cAMP, PLC-ε- 
phospholipase C-epsilon, Gapdh- glyceraldehyde 3 phosphate dehydrogenase.  
 
Primer set Forward 5’-3’ Reverse 3’-5’ Size 
(bp) 
Mouse TGR5 GAGCGTCGCCCACCACTAGG CGCTGATCACCCAGCCCCATG 104 
Mouse Gapdh AGAAACCTGCCAAGTATGATG AGAAACCTGCCAAGTATGATG 122 
Human TGR5 CTGGCCCTGGCAAGCCTCAT CTGCCATGTAGCGCTCCCCGT 277 
Human Gapdh AGGTGAAGGTCGGAGTCAACGG TTCCCGTTCTCAGCCTTGACGGT 190 
Mouse PC1 TCTGGTTGTCTGGACCTCTGAGT CAAGCCTGCCCCATTCTTT 73 
Mouse PC2 CACCTCCAAGCGGAACCA GCCAAAGAGGTGATTAAATTCA 85 
Mouse Epac1 GAGACTGGAAGAACACGGCA TCCGGTCTCATAGCCTCCAA 159 
Mouse Epac2 GTCTCACGCCAAAGGAGGAA TCCCGAAGAACAATGGAGGC 195 
Mouse PLC-ε TGGGAATGCCAACCCGCCAC CCCCTGCGGCACAGACGTTT 606 
Human PC1 CACACATGGGGAGAGAACCC GAGAAGAGGTCCCGTGCAAA 121 
Human Epac1 CTGGGACTTGGGGTCCATTC GGAACCGGTAGAATTGGGCA 130 
Human Epac2 TGATTGCTGCCCTCAAGGAG TGTGTAGGTGTGGTCCATGC 203 
Human PLC-ε CGGAAACAGTACGTCAGCCT CACCAAACAACTCCACAGCG 82 
Human β-actin AAGATCATTGCTCCTCCTGAGC TCCTGCTTGCTGATCCACATC 101 
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Table 3. Primary and secondary antibodies. Primary and secondary antibodies and 
their catalog number, product size, company name and dilution ratio. 
 
Antibody Catalog # Product size Company name Dilution Species 
TGR5 Ab72608 35-37 kDa Abcam 1:1000 Rabbit 
PC2 Sc-30166 68 and 75 kDa Santa Cruz 1:200 Rabbit 
CREB 9197 43 kDa Cell Signaling 1:1000 Rabbit 
p-CREB 9198 44 kDa Cell Signaling 1:1000 Rabbit 
β-actin A3854 42 kDa Sigma 1:25,000 Mouse 
Anti-mouse 7076  Cell Signaling 1:3000  
Anti-rabbit 7074  Cell Signaling 1:3000  
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4.3. Results 
4.3.1. Expression of TGR5 under hyperglycemia 
 To investigate the role of bile acids via TGR5 under hyperglycemic conditions, 
we firstly examined whether the expression of TGR5 is modulated by glucose 
concentrations. Expression of TGR5 mRNA was measured by qRT-PCR in MIN6 cells, 
αTC1-6 cells or control mouse islets cultured under low (5 mM) or high (25 mM) glucose 
conditions for 7 days. Expression of TGR5 was also measured in islets isolated from 
control and diabetic (db/db) mice. Expression of TGR5 was similar in islets from control 
and diabetic (db/db) mouse islets (Figure 27A). Similarly there was no change in TGR5 
expression in control mouse islets (Figure 27B), MIN6 cells (Figure 28A) or αTC1-6 
cells (Figure 28B) cultured under low (5 mM) concentrations compared to islets or cells 
cultured under high (25 mM) glucose concentrations. Thus diabetes in vivo or 
hyperglycemia in vitro had no effect on the expression of TGR5 expression. 
4.3.2. Differential expression of PC1 and PC2 in pancreatic α, β and δ cell lines 
and mouse islets 
 The effect of GLP-1 on pancreatic islet β cell function could be modulated by 
neural, endocrine or paracrine mechanisms [67]. Recent studies have shown that under 
hyperglycemia or type 2 diabetes, there is up regulation of PC1 expression in α cells 
resulting in GLP-1 secretion [129-133]. Thus under hyperglycemic conditions, 
pancreatic alpha cells are also known to be a source of GLP-1 raising the possibility that 
α cells have positive effect on insulin secretion from β cells via GLP-1 release in a 
paracrine fashion (Figure 29). This is mainly because the precursor for glucagon and 
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GLP-1 is the same i.e. Proglucagon. The processing of proglucagon by alternative 
splicing generates glucagon or GLP-1 in a cell type-specific manner due to differential 
expression of the enzymes PC1 and PC2 (Figure 30). Therefore we examined the 
basal expression of PC1 and PC2 in pancreatic α cell line, αTC1-6 cells by RT-PCR and 
western blot. RT-PCR analysis of RNA from αTC1-6 cells using specific primers 
demonstrated amplification of a PCR product of predicted size for both PC1 (73 bp) and 
PC2 (85 bp).  However, expression of PC2 was much higher when compared to PC1 
(Figure 31A). We also examined the differential expression of PC1 and PC2 in MIN6 
and TGP52 cells and mouse islets.   
 Further confirmation on the differential expression of PC1 and PC2 was obtained 
by western blot analysis using selective antibody to PC1 and PC2. The results 
demonstrated the expression of PC1 (70 kDa) and PC2 (68 kDa- mature form, 75 kDa- 
precursor form) of predicted size in the homogenates isolated from αTC1-6, MIN6 and 
TGP52 cells and mouse islets (Figure 31B). In α cells, expression of PC2 was much 
higher than PC1. In enteroendocrine cells (STC-1), in contrast, expression of PC1 was 
much higher than PC2.  
4.3.3. Hyperglycemia-induced PC1 expression is augmented by INT-777 
 As mentioned previously, under hyperglycemia or type 2 diabetes, there is 
increased expression of PC1 [129-133]. Recent studies have also shown that there is 
an elevation in the post prandial bile acid concentration in obese patients with type 2 
diabetes compared to normal healthy individuals [134]. To investigate the role of TGR5 
receptors under hyperglycemia, the effect of INT-777 on α cell PC1 expression was 
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measured at low (5 mM) or high (25 mM) glucose conditions for 7 days. Expression of 
PC1 was 2.9 fold higher in αTC1-6 cells cultured under high (25 mM) glucose conditions 
compared to cells cultured under low glucose. The effect of glucose was further 
augmented when the cells were treated with INT-777 (4.1 fold increase above 5 mM 
glucose basal) (Figure 33). Notably there was no change in the expression of PC2 in 
αTC1-6 cells cultured under high glucose conditions compared to low glucose (Figure 
32).  
 Expression of PC1 was also increased in mouse islets cultured under high 
glucose compared to islet cultured under low glucose (3.6 fold increase above 5 mM 
glucose basal). The effect of glucose was further augmented when the islets were 
treated with 25 µM INT-777 for 48 h under high glucose (5.2 fold increase above 5 mM 
glucose basal) (Figure 34). Expression of PC1 was significantly higher in islets from 
db/db mouse compared to islets from control mice (3 fold increase above control islets). 
Treatment of islets with INT-777 further augmented the increase in PC1 expression (4 
fold increase above control islets) (Figure 35).  
 Expression of PC1 was also increased in human islets cultured under high 
glucose compared to islet cultured under low glucose (1.8 fold increase above 5 mM 
glucose basal). The effect of glucose was further augmented when the islets were 
treated with 25 µM INT-777 for 48 h under high glucose (2.3 fold increase above 5 mM 
glucose basal) (Figure 36). These results suggest that activation of TGR5 under 
hyperglycemic conditions promotes PC1 expression in islet α cells.     
	  	   85 
4.3.4. Signaling mechanisms involved in TGR5-mediated PC1 expression in 
pancreatic α cells 
 The notion that PC1 expression was increased by TGR5 activation was further 
examined in αTC1-6 cells transfected with human PC1 luciferase promoter construct.  
Treatment of αTC1-6 cells with 25 mM glucose caused a significant increase in the 
promoter activity (1.8±0.15 fold increase above 5 mM glucose basal) that was further 
augmented by INT-777 (3±0.24 fold increase above 5 mM glucose basal) (Figure 37B). 
Neither glucose nor INT-777 had an effect on the promoter activity of control vector 
(pGL2 basic vector) (Figure 37A).  
 To examine the mechanisms involved in INT-777-induced PC1 expression, 
αTC1-6 cells were preincubated with INT-777 in the presence or absence of inhibitors of 
Gαs (NF449, 10 µM) or PKA (myristoylated PKI, 1 µM) and then PC1 promoter activity in 
response to 25 µM INT-777 was measured. INT-777 caused an increase in PC1 
promoter activity at high (25 mM) glucose conditions; the increase was significantly 
inhibited by NF449 (75.6±3.87% inhibition) or myristoylated PKI (100% inhibition) 
(Figure 38). These results suggest that TGR5 receptors in pancreatic α cells are Gs 
coupled and TGR5-mediated PC1 promoter activity involves PKA-dependent pathway.  
 PC1 promoter activity was shown to be regulated by the transcription factor 
CREB [131]. We next examined the effect of INT-777 on the activation of transcription 
factor CREB. Activation was measured as increase in phosphorylation of CREB in 
response to INT-777.  Consistent with the activation of PC1 promoter activity, treatment 
of αTC1-6 cells with INT-777 caused activation of CREB (Figure 39). Similarly, 
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treatment of islets from db/db mice with INT-777 caused activation of CREB compared 
to treatment of islets from control mice (Figure 40). 
  In summary, the results suggest that activation of TGR5 leads to stimulation of 
PC1 promoter activity via Gs/PKA/CREB pathway. The activated CREB bound to CBP 
then binds to the cAMP response element (CRE) region on the PC1 gene and increases 
its expression (Figure 41). 
4.3.5. Hyperglycemia-induced GLP-1 secretion is augmented by TGR5 ligands 
 Previous studies have shown that PC1 gene expression and synthesis of GLP-1 
are co-regulated, and increased PC1 expression in rat islet α cells under hyperglycemia 
leads to an increase in GLP-1 secretion [129-133]. Since we found that activation of 
TGR5 by INT-777 augmented PC1 expression in αTC1-6 cells and control mouse islets 
cultured under hyperglycemic conditions and also in diabetic mouse islets, we next 
examined the effect of TGR5 ligands on GLP-1 secretion in αTC1-6 cells as well as 
mouse islets cultured under low (5 mM) and high glucose (25 mM) conditions.  
 GLP-1 secretion from αTC1-6 cells cultured under 25 mM glucose was 
significantly higher compared to cells cultured under 5 mM glucose (2.0±0.12 fold 
increase above 5 mM glucose basal).  The effect of glucose on GLP-1 secretion was 
further augmented upon treatment of cells with INT-777 (1.8±0.3 fold increase above 25 
mM glucose basal). Similar augmentation in GLP-1 secretion was also obtained upon 
treatment of cells with LCA (1.7±0.13 fold increase above 25 mM glucose basal) 
(Figure 42). 
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 We also examined the effect of TGR5 ligands on GLP-1 secretion from mouse 
pancreatic islets cultured in low (5 mM) or high (25 mM) glucose condition for 7 days. 
GLP-1 secretion from islets cultured under 25 mM glucose was significantly higher 
compared to islets cultured under 5 mM glucose (2.6±0.17 fold increase above 5 mM 
glucose basal).  The effect of glucose on GLP-1 secretion was further augmented upon 
treatment of islets with INT-777 (1.5±0.12 fold increase above 25 mM glucose basal). 
Similar augmentation in GLP-1 secretion was also obtained upon treatment of islets with 
LCA (1.4±0.11 fold increase above 25 mM glucose basal) (Figure 43). Similarly 
treatment of diabetic (db/db) islets with 25 µM INT-777 significantly augmented GLP-1 
secretion (1.5±0.11 fold increase above db/db basal) compared to control mouse islets 
(Figure 44). 
 Similar pattern of GLP-1 secretion was obtained with human islets. GLP-1 
secretion from islets cultured under 25 mM glucose was significantly higher compared 
to islets cultured under 5 mM glucose (1.7±0.05 fold increase above 5 mM glucose 
basal). The effect of glucose on GLP-1 secretion was further augmented upon treatment 
of islets with INT-777 (1.3±0.12 fold increase above 25 mM glucose basal)  (Figure 45). 
4.3.6. Signaling mechanisms involved in TGR5-mediated GLP-1 secretion in 
pancreatic α cells 
 We next investigated the mechanisms by which INT-777 augments GLP-1 
secretion in pancreatic α cells under hyperglycemic (25 mM) conditions. To examine 
whether INT-777 induced GLP-1 secretion involves PKA-dependent or PKA-
independent mechanism, GLP-1 secretion in response to INT-777 was measured in the 
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presence of myristoylated PKI, a selective PKA inhibitor. The INT-777 induced GLP-1 
secretion was unaffected by myristoylated PKI (2.2±0.05 fold increase above 25 mM 
glucose basal) (Figure 46) suggesting that GLP-1 release from αTC1-6 cells was not 
mediated by PKA.  Treatment of αTC1-6 cells with a cAMP analog, 8-pCPT-2'-O-Me-
cAMP (Epac ligand) that activates the exchange factor, Epac (but not PKA) caused an 
increase in GLP-1 secretion (1.7±0.13 fold increase above 25 mM glucose basal) 
(Figure 47). 
 We have previously shown that bile acids via activation of TGR5 stimulates 
insulin secretion from pancreatic β cells and is mediated via Gs/Epac/PLC-ε/Ca2+ 
pathway. This pathway was similar to the one involved in TGR5-mediated GLP-1 
release in the enteroendocrine L cells [109]. RT-PCR studies also demonstrated the 
expression of Epac2 and PLC-ε in αTC1-6 cells (Figure 48).  
 We next examined the effect of INT-777 and Epac selective ligand 8-pCPT-2'-O-
Me-cAMP on PI hydrolysis in α cells. Both INT-777 and Epac ligand caused significant 
increase in PI hydrolysis (Figure 49). INT-777-induced increase in PI hydrolysis 
(1201±38 cpm/mg protein; 185±3% increase above basal levels) was blocked by 
selective inhibitors of Gαs protein (NF449, 76±5% inhibition), PI hydrolysis (U73122, 
77±6% inhibition) or Epac2 (ESI-05, 80±4% inhibition). These results suggest that 
stimulation of PI hydrolysis by INT-777 was mediated via activation of Gαs proteins, and 
cAMP-dependent Epac/PLC-ε activity. In support to this notion, the selective Epac 
ligand also stimulated PI hydrolysis (1154±20 cpm/mg protein; 173±4% increase above 
basal levels). Stimulation of PI hydrolysis by Epac ligand was inhibited by U73122 
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(66.6±3.5% inhibition) or ESI-05 (65.0±2.35% inhibition) but not by NF449 (1033±10 
cpm/mg protein; 143±35% increase above basal levels).   
 To further confirm the signaling pathway involved in TGR5-mediated GLP-1 
secretion in pancreatic α cells, we measured the effect of INT-777 on GLP-1 release in 
the presence or absence of NF449, U73122, BAPTA-AM or ESI-05. INT-777-induced 
GLP-1 secretion (2.4±0.07 fold increase above 25 mM glucose basal) was abolished by 
incubation of cells with NF449 (Gαs inhibitor), U73122 (PI hydrolysis inhibitor), BAPTA-
AM (calcium chelator) or ESI-05 (Epac 2 inhibitor) (Figure 50). 
  In summary, hyperglycemia induces PC1 expression in islet α cells leading to 
GLP-1 secretion. The effect of glucose on PC1 promoter activity, PC1 expression and 
GLP-1 secretion was augmented by activation of TGR5 receptors in response to bile 
acids. The pathway coupled to TGR5 involved sequential activation of Gs, cAMP-
dependent Epac and Epac-mediated PLC-ε activity and Ca2+ release (Figure 51) 
4.3.7. Regulation of pancreatic β cell function by GLP-1 released from α cells in 
response to bile acids  
 We have previously shown that bile acids promote glucose-induced insulin 
release via TGR5 in pancreatic β cells [116]. TGR5 receptors are expressed on 
pancreatic β cells as well as α cells and our present data suggests that activation of 
TGR5 by INT-777 under hyperglycemic conditions augments PC1 expression in 
pancreatic α cells leading to GLP-1 secretion. This raises the possibility that α cells 
have positive effect on the insulin secretion from β cells via GLP-1 release in a 
paracrine fashion. This notion was examined by measurement of insulin secretion from 
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human islets cultured under hyperglycemic conditions for 7 days. In these islets, the 
effect of INT-777 on insulin secretion was measured in the presence or absence of 0.5 
µM exendin (9-39), a GLP-1 receptor antagonist. INT-777 augmented glucose-induced 
insulin secretion in islets cultured under both 5 mM (1.9±0.02 fold increase) and 25 mM 
glucose (1.5±0.06 fold increase) (Figure 52).  The effect of INT-777 was inhibited by the 
GLP-1 receptor antagonist, exendin (9-39) in islets cultured only under 25 mM glucose. 
(52±10% inhibition)  (Figure 52). The results are consistent with the augmentation of 
glucose-induced PC1 expression by INT-777.   
 These results suggest that insulin release in response to bile acids under 
hyperglycemic conditions results from combined activation of TGR5 receptors and GLP-
1 receptors on β cells. Activation of the latter reflects the paracrine effect of GLP-1 
released from α cells upon bile acid-induced stimulation of TGR5 receptors. In in vivo 
the paracrine effect of GLP-1 could act in concert with the endocrine effect involving 
GLP-1 release from enteroendocrine cells in response to bile acids (Figure 53). 
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4.4.  Discussion 
 The link between plasma levels of bile acids and regulation of key metabolic 
components suggests the possibility that modulation of bile acids levels and their effects 
could be a therapeutic approach. TGR5 is one of the two main receptors of bile acids 
and plays an important role in the regulation of energy metabolism and glucose 
homeostasis [63,66]. In the previous chapters, we have demonstrated that TGR5 is 
expressed in both islet α and β cells and activation of these receptors causes release of 
glucagon from α cells and insulin from β cells. Activation of TGR5 expressed on the 
enteroendocrine L cells, on the other hand, causes release of GLP-1. Both GLP-1 and 
glucagon are processed from the same precursor, proglucagon by the enzymes PC1 
and PC2, respectively.  Both qPCR and western blot analysis revealed that PC2 is 
preferentially expressed in α cells, whereas PC1 is preferentially expressed in 
enteroendocrine L cells. In the present chapter, we have demonstrated that PC1 
expression can be induced in α cells by high glucose and the effect of glucose was 
further augmented by activation of TGR5 by bile acids. The conclusive evidence for the 
involvement of TGR5 in the upregulation of PC1 expression and GLP-1 secretion was 
provided using several complimentary approaches: 1) both qPCR and western bolt 
analysis showed an increase in the expression of PC1 in αTC1-6 cells and islets; 2) 
luciferase assay using human PC1 promoter construct showed an increase in promoter 
activity; and 3) ELISA measurements of GLP-1 showed an increase in GLP-1 secretion. 
The mechanism observed in αTC1-6 cells was confirmed in islets from mouse and 
human and in islets from db/db mice. In addition, we have also identified the signaling 
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pathways activated by TGR5 to mediate upregulation of PC1 expression and GLP-1 
release. PC1 upregulation was mediated via Gs/cAMP/PKA/CREB pathway, whereas 
GLP-1 secretion was mediated via Gs/cAMP/Epac/PLC-ε/Ca2+ pathway; the latter 
pathway also mediates insulin release from islet β cells and GLP-1 release from the 
enteroendocrine L cells.  
 The major stimulus for the secretion of GLP-1 from enteroendocrine L cells is the 
presence of nutrients and is secreted very rapidly (within 10-15 minutes) from the 
intestinal L cells in response to meal ingestion [89,91]. Recent studies using TGR5-/- 
mice have demonstrated that activation of TGR5 was involved in GLP-1 secretion from 
enteroendocrine L cells in response to bile acids [66]. Studies by Kohli et al., provided 
clinical significance of the mechanism by demonstrating that following Rouxen Y gastric 
bypass (RYGB) surgery there is increased circulating bile acid concentrations leading to 
GLP-1 secretion [136]. Thus the enteroendocrine L cells are not only sensitive to 
nutrients but also to bile acids to stimulate GLP-1 secretion. The pivotal role of GLP-1 is 
the glucose dependent insulinotrophic effect by binding to its specific receptors present 
on the cell membrane of the pancreatic β cells [85]. GLP-1 is also known to stimulate β 
cell proliferation and also enhance the differentiation of new β cells from progenitor cells 
present in the pancreatic duct epithelium [67]. In addition to the positive effect on insulin 
secretion, GLP-1 is also known to inhibit glucagon secretion, a counteractive hormone 
from α cells [86] ensuing an optimal effect on glucose homeostasis. However, GLP-1 is 
rapidly degraded by an endoprotease, dipeptidyl peptidase-4 (DPP-4) and making 
plasma GLP-1 levels short lived (1-2 minutes) [89]. This rapid metabolism of GLP-1 has 
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paved new therapeutic avenues in developing DPP4 inhibitors or GLP-1 receptor 
agonists for the treatment of diabetes [87,91].  
 Previous studies have demonstrated that there is increased bile acid pool and 
composition in animal models of type 1 diabetes (T1D) [136,137]. Therefore the present 
study was aimed to determine the role of the bile acids via activation of TGR5 on the 
expression and activity of PC1 in pancreatic α cells under normal and hyperglycemic 
conditions with the hypothesis that the locally produced GLP-1 may have a paracrine 
effect on the β cells to regulate insulin secretion. Our results demonstrated that priming 
of α cells with high glucose is necessary for the activation of TGR5 to up regulate PC1 
expression and stimulate GLP-1 secretion. Thus, TGR5 activation in control islets 
cultured under high (25 mM) glucose conditions or islets from diabetic (db/db) mice 
further augmented the effect of glucose on PC1 expression and GLP-1 secretion. We 
have also demonstrated that release of GLP-1 from α cells, in turn, regulates insulin 
release from β cells. This paracrine pathway provides an attractive alternative 
mechanism to regulate glucose levels. The increase in insulin secretion in response to 
TGR5 activation under hyperglycemic conditions was not due to upregulation of TGR5 
expression. Our results also showed that hyperglycemia had no effect on TGR5 
expression in both α and β cells.  Expression of TGR5 was also similar in islets from 
control and db/db mice.  Our studies are done in vitro using cell lines, mouse islets and 
human islets; therefore the in vivo relevance of this paracrine mechanism needs to be 
demonstrated.  
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 Our data showed an increase in PC1 expression under high glucose conditions 
in consistent with previous studies by other groups [131-133]. Increase in GLP-1 
secretion from α cells was demonstrated in vitro in αTC1-6 cells cultured under high 
glucose conditions, and in vivo in both type 1 and type 2 diabetic models such as NOD 
mice, STZ treated mice and ob/ob, db/db mice [129-131]. Cell therapy involving 
transplantation of encapsulated PC1 expressing α cells improved glucose handling in 
db/db mice [138-140]. It is important to note that high glucose up regulated PC1 but not 
PC2 expression. Our results are in consistent with studies by McGirr et al., [131]      
 Taken together, the studies provide evidence on the role of bile acids via TGR5 
in enabling pancreatic α cells to produce GLP-1 under high glucose conditions that can 
act locally in a paracrine mechanism to improve β cell function. Given the half life of 
plasma GLP-1, a paracrine mechanism rather than the endocrine action seems more 
effectual and physiological. In support to this notion, it is also reported that there exist 
direct intracellular contacts between α and β cells in the human islets [75,141]. 
Acetylcholine secreted by human pancreatic α cells sensitizes β cells to respond to the 
increase in glucose concentrations by acting in a paracrine manner [142]. In addition to 
factors such as high glucose, inflammatory cytokines (IL-6) [143], β cell destruction, bile 
acids could also aid in the reprogramming of pancreatic α cells causing a switch in the 
processing of proglucagon by up regulating PC1 expression and increasing GLP-1 
production, an adaptation under pathological conditions such as obesity or diabetes. 
Thus the findings in the present study opens new avenues in considering bile acids or 
bile acid mimetics as a therapeutic approach for treating type 2 diabetes.  
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Figure 26. Cell lines used in the study. Pancreatic α (αTC1-6), β (MIN6) and δ 
(TGP52) and enteroendocrine cell line (STC-1) were grown in their respective culture 
media and the cells were incubated at 37°C in 5% CO2. 
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Figure 27.  Effect of glucose on TGR5 expression in mouse islets. Total RNA 
isolated from the islets of control or diabetic (db/db) mice (A) and islets from control 
mice cultured for 7 day under low (5mM) or high (25 mM) glucose conditions (B) was 
reverse transcribed and TGR5 mRNA levels was measured by qRT-PCR. The results 
are expressed as fold change in TGR5 expression in reference to control (A) or 5 mM 
glucose basal (B) after normalizing with the endogenous control, β-actin. TGR5 
expression was found to be similar between control and db/db mouse islets and 
between islets cultured under 5 mM versus 25 mM glucose concentration. Values are 
expressed as mean ± SEM of 3 experiments. 
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Figure 28.  Effect of glucose on TGR5 expression in αTC1-6 and MIN6 cells. Total 
RNA isolated from αTC1-6 (A) and MIN6 (B) cells cultured for 7 days under low (5mM) 
or high (25 mM) glucose conditions was reverse transcribed and TGR5 mRNA levels 
was measured by qRT-PCR. The results are expressed as fold change in TGR5 
expression in reference to 5 mM glucose basal after normalizing with the endogenous 
control, β-actin. High glucose had no effect on TGR5 expression in both αTC1-6 and 
MIN6 cells. Values are expressed as mean ± SEM of 3 experiments. 
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Figure 29. Regulation of insulin secretion from pancreatic β cells via GLP-1 
(Endocrine and paracrine mechanisms).  GLP-1, the gut peptide is secreted from the 
intestinal L cells in response to bile acids. The released GLP-1 reaches the systemic 
circulation and exerts its effect upon binding to its receptors on the pancreatic β cells 
and stimulates glucose dependent insulin secretion in an endocrine fashion. Studies 
have shown that under hyperglycemic conditions, pancreatic α cells produce GLP-1 in 
response to high glucose concentrations, which in turn acts as a paracrine stimulate β 
cells to release insulin. However the role of bile acids on the paracrine mechanism is 
unknown.  
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Figure 30. Processing of proglucagon. Proglucagon is the precursor for both GLP-1 
and glucagon and is processed in a cell type specific manner. Proglucagon is 
processed to GLP-1 by prohormone convertase 1 (PC1) in the enteroendocrine L cells 
while in α cells of the pancreatic islets, proglucagon is processed to glucagon by 
prohormone convertase 2 (PC2). This tissue specific processing of proglucagon is due 
to differential expression of enzymes PC1 and PC2.  
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Figure 31. Differential expression of PC1 and PC2 in pancreatic α, β and δ cell 
lines and mouse islets. A: mRNA expression- Total RNA isolated from αTC1-6 (α), 
MIN6 (β), TGP52 (δ) cells and mouse islets was reverse transcribed and expression of 
PC1 and PC2 mRNA was examined by RT-PCR using specific primers. The results 
show representative PCR products (PC1- 73 bp, PC2- 85 bp or Gapdh- 122 bp) 
analyzed on 2% agarose gel containing ethidium bromide using Gel DocTM EZ imager. 
B: Protein expression- Cell lysates containing equal amount of total proteins from 
αTC1-6, MIN6, TGP52 cells and mouse islets were separated on SDS-PAGE and the 
expression of PC1 and PC2 was analyzed using selective antibody. PC1 with the 
molecular weight of 70 kDa and PC2 with a molecular weight of 75 kDa (precursor) and 
68 kDa (mature form) were detected by chemilumiscence. The membrane was 
reprobed for β-actin (42 kDa), an endogenous loading control. 
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Figure 32.  Effect of glucose and INT-777 on PC2 expression in αTC1-6 cells. Total 
RNA isolated from αTC1-6 cells cultured for 7 days under low (5mM) or high glucose 
(25 mM) glucose conditions in the presence or absence of INT-777 (48 hours) was 
reverse transcribed and PC2 mRNA levels was measured by qRT-PCR. The results are 
expressed as fold change in PC2 expression levels in reference to 5 mM or 25 mM 
glucose basal after normalizing with the endogenous control, β-actin. PC2 expression 
was found to be unchanged under conditions of hyperglycemia (25 mM glucose) and 
INT-777 also had no effect on the expression of PC2. Values are expressed as mean ± 
SEM of 3 experiments. 
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Figure 33. Increased PC1 expression in response to glucose and INT-777 in αTC1-
6 cells. A: qRT-PCR- Total RNA isolated from αTC1-6 cells cultured for 7 days under 
low (5mM) or high (25 mM) glucose conditions in the presence or absence of INT-777 
(48 hours) was reverse transcribed and PC1 mRNA levels was measured by qRT-PCR. 
The results are expressed as fold change in PC1 expression levels after normalizing 
with the endogenous control, β-actin. PC1 expression was increased under high (25 
mM) glucose conditions and the increase was further augmented upon treatment with 
INT-777. Values are expressed as mean ± SEM of 3 experiments. ##p<0.001 vs. 5 mM 
glucose basal; **p<0.001 vs. 25 mM glucose basal. B: Protein expression- Cell lysates 
containing equal amounts of total proteins from αTC1-6 cells cultured for 7 days under 
low (5 mM) or high (25 mM) glucose conditions in the presence or absence of INT-777 
(48 hours) were separated on SDS-PAGE and the expression of PC1 (70 kDa) was 
analyzed using selective antibody. Protein bands were visualized with enhanced 
chemiluminescence, images were quantified and densitometric values were calculated 
after normalization to β-actin density.  
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Figure 34. Increase in PC1 expression in response to glucose and INT-777 in 
control mouse islets. Total RNA isolated from control mouse islets cultured for 7 days 
under low (5 mM) or high (25 mM) glucose conditions in the presence or absence of 
INT-777 (48 hours) was reverse transcribed and PC1 mRNA levels was measured by 
qRT-PCR. The results are expressed as fold change in PC1 expression levels in 
reference to 5 mM glucose basal after normalizing with the endogenous control, β-actin. 
PC1 expression was increased under high glucose condition and the increase was 
further augmented upon treatment with INT-777. Values are expressed as mean ± SEM 
of 3 experiments. ##p<0.001 vs. 5 mM glucose basal; **p<0.001 vs. 25 mM glucose 
basal.	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Figure 35.  Increase in PC1 expression in response to INT-777 in diabetic mouse 
islets. A: qRT-PCR- Total RNA isolated from control and diabetic (db/db) mouse islets 
cultured for 2 days in the presence or absence of INT-777 was reverse transcribed and 
PC1 mRNA levels was measured by qRT-PCR. The results are expressed as fold 
change in PC1 expression levels in reference to control basal after normalizing with the 
endogenous control, β-actin. PC1 expression was increased in db/db mouse islets and 
the increase was further augmented upon treatment with INT-777. Values are 
expressed as mean ± SEM of 3 experiments. ##p<0.001 vs. 5 mM glucose basal; 
*p<0.05 vs. 25 mM glucose basal. B: Protein expression- Cell lysates containing equal 
amounts of total proteins from control and diabetic (db/db) mouse islets cultured for 48 
hours in the presence or absence of INT-777 were separated on SDS-PAGE and the 
expression of PC1 (70 kDa) was analyzed using selective antibody. Protein bands were 
visualized with enhanced chemiluminescence, images were quantified and 
densitometric values were calculated after normalization to β-actin density.  
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Figure 36: Increased PC1 expression in response to glucose and INT-777 in 
human islets. Total RNA isolated from human islets cultured for 7 days under low (5 
mM) or high (25 mM) glucose conditions in the presence or absence of INT-777 (48 
hours) was reverse transcribed and PC1 mRNA levels was measured by qRT-PCR. The 
results are expressed as fold change in PC1 expression levels in reference to 5 mM 
glucose basal after normalizing with the endogenous control, β-actin. PC1 expression 
was increased under high glucose condition and the increase was further augmented 
upon treatment with INT-777. Values are expressed as mean ± SEM of 3 experiments. 
##p<0.001 vs. 5 mM glucose basal; *p<0.05 vs. 25 mM glucose basal.	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Figure 37.  Increase in PC1 promoter activity in response to glucose and INT-777 
in αTC1-6 cells. The PC1 promoter-luciferase reporter construct containing CRE 
motifs- DNA from 971 to 1 bp (PC1 vector) or pGL2 basic vector (control vector) were 
transiently transfected into αTC1-6 cells. After 24 hours of transfection, cells were 
treated with 5 mM or 25 mM glucose with or without INT-777 for 24 hours. Cells were 
lysed and luciferase activity was measured in the cell supernatants using BrightGlo 
assay kit in a luminometer. High (25 mM) glucose-induced PC1 promoter activity and 
the increase were further augmented by INT-777. The results are expressed as mean ± 
SEM of 5 experiments. ##p<0.001 or #p<0.05  vs. 5 mM glucose basal; **p<0.001 vs. 25 
mM glucose basal.	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Figure 38. Effect of Gαs and PKA inhibitors on INT-777-induced PC1 promoter 
activity. αTC1-6 cells were transiently transfected with PC1 promoter-luciferase 
reporter construct using lipofectamine. Cells were treated with 5 mM glucose or 25 mM 
glucose with or without INT-777 for 24 hours in the presence or absence of selective 
Gαs inhibitor (NF449, 10 µM) or PKA inhibitor (myristoylated PKI, 1 µM). Cells were 
lysed and luciferase activity was measured in the cell supernatants using BrightGlo 
assay kit in a luminometer. High (25 mM) glucose-induced PC1 promoter activity was 
augmented by INT-777 and the effect of INT-777 was inhibited by NF449 or 
myristoylated PKI (PKI). The results are expressed as mean ± SEM of 4 experiments. 
##p<0.001 vs. 5 mM glucose basal; **p<0.001 vs. 25 mM glucose basal.	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Figure 39. Activation of CREB in response to glucose and INT-777 in αTC1-6 cells. 
αTC1-6 cells were cultured under low (5mM) or high (25 mM) glucose conditions for 7 
days. The cells were then washed and treated with INT-777 for 1 hour. Cell lysates 
containing total proteins were separated on SDS-PAGE and the expression of CREB 
and p-CREB (43 kDa) was analyzed using selective antibody. Protein bands were 
visualized with enhanced chemiluminescence, images were quantified and 
densitometric values were calculated after normalization to CREB density.  
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Figure 40. Activation of CREB in response to INT-777 in db/db mouse islets.	  	  
Cell lysates containing equal amounts of total proteins from control and diabetic (db/db) 
mouse islets treated with INT-777 for 1 hour were separated on SDS-PAGE and the 
expression of CREB and p-CREB (43 kDa) was analyzed using selective antibody. 
Protein bands were visualized with enhanced chemiluminescence, images were 
quantified and densitometric values were calculated after normalization to CREB 
density. 	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Figure 41. Schematic representation of the signaling pathway coupled to TGR5 
receptors to mediate PC1 expression in pancreatic α cells. TGR5 receptors 
expressed in the pancreatic α cells are Gαs coupled, and activation of these receptors 
by bile acids leads to the generation of cAMP and activation of PKA.  Activation of PKA 
leads to activation of CREB and the activated CREB in the presence of CBP binds to 
the cAMP response element (CRE) region on the PC1 gene and increases its 
expression.  	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Figure 42. Augmentation of hyperglycemia-induced GLP-1 secretion by TGR5 
ligands in αTC1-6 cells.  αTC1-6 cells were plated at a density of 2 x 105 cells in 24-
well plates with DMEM containing 5 mM glucose or 25 mM glucose and cultured for 6 
days. The cells were then washed and incubated in DMEM containing 5 mM or 25 mM 
glucose with or without INT-777 or LCA for 24 hours. The supernatants were collected 
and GLP-1 secretion was measured by ELISA. High (25 mM) glucose induced GLP-1 
secretion and the increase was further augmented by INT-777 or LCA. Values are 
expressed as mean ± SEM of 4 experiments. ##p<0.001 vs. 5 mM glucose basal;  
**p<0.001 vs. 25 mM glucose basal. 
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Figure 43. Augmentation of hyperglycemia-induced GLP-1 secretion by TGR5 
ligands in control mouse islets. The islets isolated from the control mice were 
cultured in RPMI-1640 medium containing 5 mM glucose or 25 mM glucose for 6 days. 
The islets (25-30 islets/condition) were then washed and incubated in RPMI-1640 
containing 5 mM or 25 mM glucose with or without INT-777 or LCA for 24 hours. The 
supernatants were collected and GLP-1 secretion was measured by ELISA. High (25 
mM) glucose induced GLP-1 secretion and the increase was further augmented in 
response to activation of TGR5 by INT-777 or LCA. Values are expressed as mean ± 
SEM of 4 experiments. ##p<0.001 vs. 5 mM glucose basal;  **p<0.001 vs. 25 mM 
glucose basal. 	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Figure 44. Augmentation of GLP-1 secretion by INT-777 in diabetic (db/db) mouse 
islets. The islets isolated from the control or diabetic (db/db) mice were incubated in 
RPMI-1640 with or without INT-777 for 24 hours. The supernatants were collected and 
GLP-1 secretion was measured by ELISA. GLP-1 secretion was higher in diabetic islets 
when compared to control mouse islets. Activation of TGR5 by INT-777 augmented 
GLP-1 secretion from db/db mouse islets, but not from control mouse islets. Values are 
expressed as mean ± SEM of 4 experiments. ##p<0.001 vs. control basal;  *p<0.05 vs. 
db/db basal. 
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Figure 45: Stimulation of hyperglycemia-induced GLP-1 secretion by TGR5 
ligands in human islets. The human islets were cultured in CMRL-1066 medium 
containing 5 mM glucose or 25 mM glucose for 6 days. The islets (30-35 
islets/condition) were then washed and incubated in CMRL-1066 containing 5 mM or 25 
mM glucose with or without INT-777 for 24 hours. The supernatants were collected and 
GLP-1 secretion was measured by ELISA. High (25 mM) glucose induced GLP-1 
secretion and the increase was further augmented in response to activation of TGR5 by 
INT-777. Values are expressed as mean ± SEM of 3 experiments. #p<0.05 vs. 5 mM 
glucose basal;  *p<0.05 vs. 25 mM glucose basal. 
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Figure 46. Effect of PKA inhibitor on INT-777-induced GLP-1 secretion. αTC1-6 
cells cultured for 7 days under high (25 mM) glucose were treated with INT-777 (25 µM) 
in the presence or absence of PKA inhibitor (myristoylated PKI, 1 µM). After 1 hour, the 
supernatant was collected and GLP-1 secretion was measured by ELISA. The TGR5 
ligand, INT-777 stimulated GLP-1 secretion and the selective PKA inhibitor, 
myristoylated PKI (Myr PKI) had no effect on INT-777-induced GLP-1 secretion. Values 
are expressed as mean ± SEM of 4 experiments. **p<0.001 vs. 25 mM glucose basal. 	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Figure 47. Stimulation of GLP-1 secretion by Epac ligand. αTC1-6 cells cultured for 
7 days under high (25 mM) glucose were treated with the Epac ligand, 8-pCPT-2'-O-Me-
cAMP (10 µM). After 1 hour, the supernatant was collected and GLP-1 secretion was 
measured by ELISA. The Epac ligand significantly stimulated GLP-1 secretion from 
αTC1-6 cells. Values are expressed as mean ± SEM of 4 experiments. *p<0.05 vs. 25 
mM glucose basal. 
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Figure 48. Expression of Epac1, Epac2 or PLC-ε in αTC1-6 cells. Total RNA was 
isolated from cultured αTC1-6 cells and reverse transcribed using 1 µg of total RNA. 
The cDNA was amplified using specific primers and examined for the expression of 
Epac1 (159 bp), Epac2 (195 bp) or PLC-ε (606 bp) by RT-PCR. The results show 
representative PCR products analyzed on 2% agarose gel containing ethidium bromide 
using Gel DocTM EZ imager. Gapdh (122 bp) was used as a loading control. 
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Figure 49. Activation of PI hydrolysis by TGR5 or Epac ligand in αTC1-6  cells.  
αTC1-6  cells were labeled with myo-[3H] inositol for 24 h and then treated with INT-777 
(25 µM) or Epac ligand (8-pCPT-2'-O-Me-cAMP, 10 µM) with or without the selective 
Gαs inhibitor (NF449, 10 µM), PI hydrolysis inhibitor (U73122, 10 µM) or Epac2 inhibitor 
(ESI-05, 5 µM). PI hydrolysis was measured by ion exchange chromatography and the 
results are expressed as percent increase above basal levels.  INT-777 or Epac ligand 
stimulated PI hydrolysis and the stimulation were blocked with the pretreatment of cells 
with U73122 and ESI-05. NF449 inhibited PI hydrolysis stimulated by INT-777 but not 
by Epac ligand. Values are expressed as mean ± SEM of 3 experiments. **p<0.001 
significant inhibition in PI hydrolysis compared to INT-777 or Epac ligand.  	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Figure 50. Effect of Gαs, PI hydrolysis, Epac2 inhibitor and calcium chelator on 
INT-777-induced GLP-1 release.  αTC1-6 cells cultured for 7 days under high (25 mM) 
glucose were treated with INT-777 (25 µM) in the presence or absence of selective Gαs 
inhibitor (NF449, 10 µM), PI hydrolysis inhibitor (U73122, 10 µM), Epac2 inhibitor (ESI-
05, 5 µM) or calcium chelator (BAPTA-AM, 10 µM). After 1 hour, the supernatant was 
collected and GLP-1 secretion was measured by ELISA. The TGR5 ligand, INT-777 
stimulated GLP-1 secretion and stimulation was abolished by the blockade of Gαs 
activation, PI hydrolysis, Epac2 activation or chelation of Ca2+. Values are expressed as 
mean ± SEM of 3 experiments. **p<0.001 vs. 25 mM glucose basal. 	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Figure 51. Schematic representation of the signaling pathway coupled to TGR5 
receptors to mediate PC1 expression and GLP-1 secretion from pancreatic α 
cells. TGR5 receptors expressed in the pancreatic α cells are Gαs  coupled and 
activation of these receptors by bile acids leads to the generation of cAMP and 
activation of PKA. Increase in PC1 expression is mediated via PKA-dependent 
mechanism involving activation of CREB while stimulation of GLP-1 release involves 
PKA-independent mechanism via Epac/PLC-ε/Ca2+ pathway. 	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Figure 52: Effect of Exendin (9-39) on INT-777-induced insulin secretion in human 
islets. The human islets were cultured in CMRL-1066 medium containing 5 mM glucose 
or 25 mM glucose for 7 days. The islets (30-35 islets/condition) were treated with INT-
777 (25 µM) in the presence or absence of exendin (9-39) for 1 hour. The supernatants 
were collected and insulin secretion was measured by ELISA. INT-777 augmented 
glucose-induced insulin secretion in islets cultured under both 5 mM and 25 mM 
glucose.  The effect of INT-777 was inhibited by the GLP-1 receptor antagonist, exendin 
(9-39) in islets cultured only under 25 mM glucose. Values are expressed as mean ± 
SEM of 3 experiments. **p<0.001 vs. 25 mM glucose basal; ##p<0.001 significant 
inhibition of INT-777-induced insulin secretion.	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Figure 53.  Regulation of pancreatic α and β cell function by the bile acid receptor 
TGR5. (Left panel) Under normal conditions, activation of TGR5 receptors on the 
pancreatic β cells by bile acids leads to release of insulin.  Activation of TGR5 receptors 
on the pancreatic α cells by bile acids leads to release of glucagon, which is processed 
from proglucagon by the selective expression of prohormone convertase 2 (PC2) in 
these cells. Insulin and glucagon act to oppose each other action to regulate blood 
glucose levels. (Right panel) Under chronic hyperglycemia or diabetes, activation of 
TGR5 receptors on α cells augments glucose-induced PC1 expression and GLP-1 
secretion, which in turn, acts in a paracrine manner to promote insulin secretion from β 
cells. Thus, in diabetes, secretions of α and β cells act in concert to regulate blood 
glucose levels. 
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CHAPTER	  5	  
GENERAL	  DISCUSSION	  	  	  	   Bile acids, the end product of cholesterol metabolism, are made in hepatocytes 
and stored in gallbladder [1]. In humans, cholic acid and chenodeoxycholic acid are the 
primary bile acids, and deoxycholic acid and lithocholic acid are the secondary bile 
acids. Bile acids are released in response to a meal upon gallbladder contraction. This 
results in an increased bile acid concentration in the gut postprandially [4]. The 
physiological function of bile acids as emulsifying agents to facilitate lipid digestion and 
absorption in the gut is well established [2]. Most of the bile acids secreted into the 
duodenum are reabsorbed in the distal ileum and redirected to liver via hepatic portal 
circulation [5]. The concentration of bile acids within the intestinal lumen and in the 
circulation varies in an episodic fashion. After a meal, bile acid levels increase in the 
portal vein and liver and also in the systemic circulation [5,40]. The concentration of bile 
acids reaches up to 15 µM under postprandial condition [5].   
Recent studies have established the role of bile acids as signaling molecules with 
the identification of specific nuclear (FXR) and a plasma membrane G-protein coupled 
receptors (TGR5) for which bile acids are physiological ligands [24-26,35,36]. Activation 
of these receptors plays an important role in several physiological functions such as 
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hepatic bile flow, immune responses, cell proliferation, gastrointestinal motility and 
secretion, energy metabolism and glucose homeostasis. The expression of FXR and 
TGR5 is ubiquitous and are known to have distinct functional roles [30-35, 38-42].   
The role of TGR5 in the regulation of glucose metabolism via release of GLP-1 
from enteroendocrine L cells has gained a lot of interest as GLP-1 exerts its biological 
effects via the activation of GLP-1 receptors to release insulin from the pancreatic 
β cells [65,67]. Insulin secretion, in addition to glucose, is regulated by fatty acids, amino 
acids and by neurohumoral agents via activation of specific G protein coupled receptors 
[81,99-103]. The expression and function of TGR5 in pancreatic islets are unknown. 
Hence our studies were aimed to examine the direct effect of bile acids via TGR5 on the 
pancreatic α and β cells. 
Role of TGR5 in pancreatic β cell function 
 We have identified the expression of TGR5 receptors on the β cells and 
demonstrated that activation of these receptors by bile acids stimulates insulin secretion 
in a glucose dependent manner. Evidence for the specific involvement of TGR5 in 
insulin secretion was obtained in MIN6 cells (β cell line) and islets isolated from human 
and mouse pancreas using various ligands: oleanolic acid (selective ligand for TGR5), 
INT-777 (specific ligand for TGR5) and lithocholic acid (physiological ligand that 
preferentially activates TGR5). LCA at the physiological concentrations (10-25 µM) 
induced insulin secretion underlying the physiological significance of TGR5 receptors in 
β cells. We further elucidated the signaling mechanism involved in TGR5-mediated 
insulin secretion in β cells using both biochemical and pharmacological approaches. We 
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provided evidence that β cell TGR5 receptors are coupled to Gs and stimulation of 
adenylyl cyclase leading to generation of cAMP. Insulin release in response to TGR5 
activation uses non-canonical pathway that is independent of PKA.  Activation of cAMP 
dependent Epac/PLC-ε/Ca2+ pathway stimulates insulin secretion. Activation of TGR5 in 
β cells leads to stimulation of PI hydrolysis and increase in intracellular Ca2+, a 
biochemical measure of PLC-ε activity and IP3-dependent Ca2+ release pathway. In Our 
studies, we also demonstrated that insulin secretion in response to TGR5 activation was 
blocked by inhibitors of Gs (NF449), and PI hydrolysis (U73122) and intracellular Ca2+ 
chelator (BAPTA-AM), but not by inhibitor of PKA (myristoylated PKI). We have also 
demonstrated the expression of Epac and PLC-ε in β cells and release of insulin in 
response to Epac-selective ligand, 8-pCPT-2'-O-Me-cAMP. These studies provide 
conclusive evidence that activation of β cell TGR5 by bile acids causes insulin release 
via Gs/cAMP/PLC-ε/Ca2+ pathway. Thus, bile acids, in addition to regulating insulin 
release via GLP-1 secretion from enteroendocrine L cells, also directly acts on TGR5 
receptors in β cells to promote insulin release. The signaling pathway involved in insulin 
secretion from β cells was found to be similar to the secretion of GLP-1 from 
enteroendocrine L cells in response to TGR5 activation [109].  
Pancreatic islets are composed of insulin producing β cells, glucagon producing 
α cells along with other cell types [68,74,75]. The blood glucose levels are well 
regulated by the opposing actions of insulin and glucagon secreted from the islets [119]. 
The normal glycemic levels in the body are determined by the insulin to glucagon ratio. 
Under postprandial conditions, the secretion of insulin from β cells reduces blood 
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glucose levels and during the fasted state, the secretion of glucagon from α cells acts as 
a counter regulatory hormone and increases blood glucose levels [118]. Studies have 
shown that secretion of glucagon from α cells are modulated by not only low glucose 
concentrations but also by nutrients such as amino acids, fatty acids; neurotransmitters 
like acetylcholine, epinephrine and also hormones such as cholecystokinin, GLP-1, 
somatostatin etc [68,120]. In our next study we examined the effect of bile acids on the 
regulation of glucagon secretion from α cells. 
Role of TGR5 in pancreatic α cell function 
 We have identified the expression of TGR5 receptors in α cells and 
demonstrated that activation of these receptors by bile acids stimulates glucagon 
secretion under low glucose conditions. Evidence for the specific involvement of TGR5 
in glucagon secretion was obtained in αTC1-6 cells (α cell line) and islets isolated from 
mouse pancreas using pharmacological (OA and INT-777) and physiological (LCA) 
ligands.  The physiological significance of TGR5 receptors in α cells needs to be 
determined given the fact that glucagon secretion occurs under hypoglycemic condition 
and concentration of bile acids are lower under ‘fasted state’. Glucagon and GLP-1 are 
derived from the same precursor, proglucagon by the enzymes PC2 and PC1, 
respectively. Activation of TGR5 in enteroendocrine L cells causes GLP-1 secretion, 
whereas activation in α cells causes glucagon secretion. This is due to cell-specific 
expression PC1 and PC2. PC2 is preferentially expressed in α cells and PC1 is 
preferentially expressed in enteroendocrine L cells. Recent studies have shown that in 
islet α cells under hyperglycemic conditions there is a switch in the processing of 
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proglucagon to GLP-1 [131-133]. Transplantation of encapsulated α cells into db/db 
mice improved glucose handling in these mice [139-140] suggesting that secretion from 
α cells facilitate insulin secretion from β cells. Recent studies have also shown that 
there is increase in bile acid pool in animal models of diabetes. These studies led us to 
examine the hypothesis that activation of TGR5 receptors in α cells under 
hyperglycemia up regulates PC1 expression leading to GLP-1 secretion. 
Paracrine regulation of insulin secretion by GLP-1 released from α cells 
 Our studies suggest that bile acids could aid in the reprogramming of pancreatic 
α cells causing a switch in the processing of proglucagon by up regulating PC1 
expression and increasing GLP-1 production, an adaptation under pathological 
conditions such as obesity or diabetes. Under normal conditions, PC2 expression is 
more abundant in α cells.  Hyperglycemic conditions, however, up regulated PC1, but 
not PC2 expression in α cells and the effect of glucose was further augmented by TGR5 
activation. Glucose-induced GLP-1 release from α cells was also augmented by the 
activation of TGR5 receptors. Augmentation of glucose-induced PC1 expression and 
GLP-1 secretion by bile acids was demonstrated in αTC1-6 cells and in islets from 
mouse and human.  Furthermore, our studies showed that release of GLP-1 from 
diabetic (db/db) mice islets was augmented by TGR5 receptor activation. We have also 
identified distinct signaling pathways involved in the activation of PC1 and release of 
GLP-1 in response to TGR5 activation. Stimulation of PC1 promoter activity involved 
Gs/cAMP/PKA pathway and PKA-dependent activation of the transcription factor, 
CREB, whereas stimulation of GLP-1 release involved Gs/cAMP/Epac/PLC-ε/Ca2+ 
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pathway. GLP-1 released from α cells acts on GLP-1 receptors on β cells and facilitates 
insulin secretion. This paracrine pathway provides a compensatory mechanism under 
hyperglycemic conditions to regulate glucose homeostasis. This paracrine mechanism 
involving GLP-1 release from α cells will be more significant given the fact that 
concentrations of GLP-1 from enteroendocrine L cells are short-lived due to degradation 
via peptidases. In support to this notion, it is also reported that there exist direct 
intracellular contacts between α and β cells in the human islets [75,141].  
 
Potential implications on human health 
 Type 2 diabetes mellitus (T2D) is a major cause of morbidity and mortality in 
many parts of the world. It is driven by insulin resistance and pancreatic β cell stress 
eventually leading to β cell exhaustion and death [114,115]. GLP-1, in addition to its 
insulinotrophic effect in type 2 diabetes, is also known to regulate β cell mass by 
increasing β cell proliferation and survival by exerting anti-apoptotic effect [67,86]. 
Therefore TGR5 signaling in T2D in humans resulting in GLP-1 secretion from 
pancreatic α cells is very promising with the hope of considering TGR5 ligands for the 
management and therapy of T2D.  
 The current studies may also have implications for another devastating disease 
namely pancreatic adenocarcinoma. This malignancy often develops in those with 
diabetes and insulin resistance is a well-known risk factor [144]. GLP-1 receptors are 
also present in pancreatic ductal cells and acinar tissues [67]. We hypothesize that 
prolonged GLP-1 secretion by the pancreatic islets under hyperglycemic conditions 
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such as that seen in diabetes may trigger pancreatic ductal hyperplasia and cancer. 
This possibility is supported by the data that incretin based therapies mediate increased 
ductal cell proliferation in patients with obesity or T2D, a risk factor for pancreatic 
adenocarcinoma [145]. An important future direction for our work will be to confirm or 
refute this possibility. 
 
 In conclusion, we have identified the expression of TGR5 in both pancreatic α 
and β cells. Activation of these receptors by bile acids causes release of insulin from β 
cells and glucagon from α cells. Under normal conditions, glucagon counter regulates 
the function of insulin. Under hyperglycemic conditions, however, release of GLP-1 due 
to upregulation of PC1 expression promotes insulin release to facilitate glucose 
homeostasis. Thus the role of TGR5 activated by bile acids makes it a potential target to 
treat type 2 diabetes and metabolic syndrome. The knowledge gathered from this study 
has promising therapeutic potential and opens new avenues in considering TGR5 
agonists for the treatment of metabolic syndrome.  	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